[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 60 of about 60
1. Mackley HB, Videtic GM: Primary carcinoid tumors of the lung: a role for radiotherapy. Oncology (Williston Park); 2006 Nov;20(12):1537-43; discussion 1544-5, 1549
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary carcinoid tumors of the lung: a role for radiotherapy.
  • Primary neuroendocrine neoplasms of the lung represent a clinical spectrum of tumors ranging from the relatively benign and slow-growing typical carcinoid to the highly aggressive small-cell lung carcinoma.
  • [MeSH-major] Carcinoid Tumor / radiotherapy. Lung Neoplasms / radiotherapy. Neoplasm Recurrence, Local / radiotherapy

  • MedlinePlus Health Information. consumer health - Carcinoid Tumors.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17153907.001).
  • [ISSN] 0890-9091
  • [Journal-full-title] Oncology (Williston Park, N.Y.)
  • [ISO-abbreviation] Oncology (Williston Park, N.Y.)
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 50
  •  go-up   go-down


2. Avcu S, Ozen O, Bulut MD, Bora A: Hepatic metastases of primary jejunal carcinoid tumor: A case report with radiological findings. N Am J Med Sci; 2009 Nov;1(6):305-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hepatic metastases of primary jejunal carcinoid tumor: A case report with radiological findings.
  • CONTEXT: Carcinoid tumors represent a group of well-differentiated tumors originating from the diffuse endocrine system outside the pancreas and thyroid.
  • The overall prevalence of carcinoid tumors in the United States is estimated to be one to two cases per 100,000 persons.
  • Various sites of origin of this neoplasm are appendix - 30-45%, small bowel - 25-35% (duodenum 2%, jejunum 7%, ileum 91%, multiple sites 15-35%), rectum 10-15%, caecum - 5%, and stomach - 0.5%.
  • CASE REPORT: Here we report a case of primary jejunal carcinoid tumor in a 66-year-old woman metastasizing to liver with ultrasonography, computed tomography, and diffusion-weighted magnetic resonance imaging (DWI) findings.
  • CONCLUSION: Primary jejunal carcinoid tumor is a rare entity.
  • DWI can help in the differential diagnosis of hepatic hypervascular metastatic mass lesions from benign ones, as well as in the diagnosis of carcinoid tumor.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 22666712.001).
  • [ISSN] 2250-1541
  • [Journal-full-title] North American journal of medical sciences
  • [ISO-abbreviation] N Am J Med Sci
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Other-IDs] NLM/ PMC3364631
  • [Keywords] NOTNLM ; Carcinoid / diffusion weighted MRI / jejunum / metastases / small bowel
  •  go-up   go-down


3. Langfort R, Rudziński P, Burakowska B: [Pulmonary neuroendocrine tumors. The spectrum of histologic subtypes and current concept on diagnosis and treatment]. Pneumonol Alergol Pol; 2010;78(1):33-46
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Pulmonary neuroendocrine tumors. The spectrum of histologic subtypes and current concept on diagnosis and treatment].
  • Neuroendocrine tumors of the lung represent a broad spectrum of morphologic types that share specific morphologic, immunohistochemical, ultrastructural, and molecular characteristics.
  • The classification of neuroendocrine lung tumors has changed over the last decades and currently four categories are distinguished: typical carcinoid tumor, atypical carcinoid tumor, large cell neuroendocrine carcinoma and small cell carcinoma.
  • Neuroendocrine tumors of the lung comprise approximately 20% of all primary lung cancers.
  • Because of differences in clinical behavior, therapy, and prognosis, a reliable histological diagnosis, as well as clinical and pathological staging system are essential for an appropriate medical proceedings.
  • All carcinoids are malignant tumors with the potential to metastasize.
  • The majority of patients with pulmonary carcinoid have an excellent survival, even if they present with lymph node metastases.
  • Large cell neuroendocrine and small cell carcinoma progress rapidly and are generally widespread at the moment of diagnosis.
  • Increased knowledge about pulmonary neuroendocrine tumors biology and the genetic characteristics, imply that carcinoid tumors appear to have a different etiology and pathogenesis than large cell neuroendocrine and small cell carcinoma.
  • In practice, it could be easiest to conceptualize this group of pulmonary tumors as a spectrum of malignancy ranging from the low grade typical carcinoid to the highly malignant large cell neuroendocrine and small cell carcinoma.
  • Typical carcinoid tumors associated with a fairly benign behavior should be classified as low-grade neuroendocrine tumor/carcinoma (G1) and atypical carcinoid tumors as intermediate-grade tumor/carcinoma (G2).
  • Whereas, large cell neuroendocrine and small cell carcinoma should be grouped together under the designation of high-grade neuroendocrine tumor/carcinoma (G3).
  • [MeSH-major] Lung Neoplasms / diagnosis. Lung Neoplasms / therapy. Neuroendocrine Tumors / diagnosis. Neuroendocrine Tumors / therapy
  • [MeSH-minor] Carcinoid Tumor / diagnosis. Carcinoid Tumor / therapy. Carcinoma, Large Cell / diagnosis. Carcinoma, Large Cell / therapy. Carcinoma, Small Cell / diagnosis. Carcinoma, Small Cell / therapy. Humans. Lung / pathology. Lymphatic Metastasis. Neoplasm Staging. Prognosis. Survival Analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20162517.001).
  • [ISSN] 0867-7077
  • [Journal-full-title] Pneumonologia i alergologia polska
  • [ISO-abbreviation] Pneumonol Alergol Pol
  • [Language] pol
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Poland
  • [Number-of-references] 67
  •  go-up   go-down


Advertisement
4. Ferlito A, Silver CE, Bradford CR, Rinaldo A: Neuroendocrine neoplasms of the larynx: an overview. Head Neck; 2009 Dec;31(12):1634-46
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Neuroendocrine neoplasms of the larynx are rare but are the most common nonsquamous tumors of this organ.
  • In the past, there has been considerable confusion about the nature and classification of these neoplasms, but the current consensus is that there are 4 different types of laryngeal neuroendocrine tumors composed of paraganglioma, typical carcinoid, atypical carcinoid tumor, and small cell neuroendocrine carcinoma.
  • Diagnosis is based primarily on light microscopy and confirmed by immunohistochemistry and electron microscopy.
  • Precise diagnosis is essential because the natural history, treatment, and prognosis vary widely for the different neoplastic categories.
  • Atypical carcinoid tumors are more common and more aggressive.
  • Small cell neuroendocrine carcinomas are highly aggressive and should be considered disseminated at initial diagnosis.
  • Atypical carcinoid tumors have a 5-year survival rate of approximately 50%, which decreases with time.
  • The biological behavior of laryngeal paraganglioma is generally benign and the prognosis is excellent.
  • [MeSH-major] Laryngeal Neoplasms / pathology. Laryngeal Neoplasms / therapy. Neuroendocrine Tumors / pathology. Neuroendocrine Tumors / therapy
  • [MeSH-minor] Carcinoid Tumor / mortality. Carcinoid Tumor / pathology. Carcinoid Tumor / therapy. Carcinoma, Small Cell / mortality. Carcinoma, Small Cell / pathology. Carcinoma, Small Cell / therapy. Chemotherapy, Adjuvant. Combined Modality Therapy. Female. Humans. Laryngectomy / methods. Male. Neck Dissection / methods. Neoplasm Staging. Paraganglioma / mortality. Paraganglioma / pathology. Paraganglioma / therapy. Prognosis. Radiotherapy, Adjuvant. Risk Assessment. Survival Analysis

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19536850.001).
  • [ISSN] 1097-0347
  • [Journal-full-title] Head & neck
  • [ISO-abbreviation] Head Neck
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 89
  •  go-up   go-down


5. Kazakov DV, Kutzner H, Rütten A, Mukensnabl P, Michal M: Carcinoid-like pattern in sebaceous neoplasms: another distinctive, previously unrecognized pattern in extraocular sebaceous carcinoma and sebaceoma. Am J Dermatopathol; 2005 Jun;27(3):195-203
MedlinePlus Health Information. consumer health - Carcinoid Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Carcinoid-like pattern in sebaceous neoplasms: another distinctive, previously unrecognized pattern in extraocular sebaceous carcinoma and sebaceoma.
  • This report emphasizes a carcinoid-like pattern, a previously unrecognized feature in cutaneous sebaceous neoplasms.
  • We report 7 patients with sebaceous tumors in which neoplastic cells were arranged in a trabecular and ribbon-like pattern or formed rosettes/pseudorosettes.
  • The cases included 6 men and 1 woman, with their ages at the diagnosis ranging from 43 to 87 years (median age, 59).
  • The carcinoid-like arrangement of neoplastic cells was the sole pattern in 4 cases, and in 3 cases the so-called labyrinthine/sinusoidal and/or rippled patterns were seen in addition.
  • Although the neoplasm appeared benign architecturally, the presence of cytologic atypia qualified 2 tumors as low-grade carcinomas.
  • We conclude that the carcinoid-like pattern is another distinctive pattern indicative of sebaceous neoplasms.
  • [MeSH-major] Adenocarcinoma, Sebaceous / pathology. Biomarkers, Tumor / analysis. Carcinoid Tumor / pathology. Sebaceous Gland Neoplasms / pathology
  • [MeSH-minor] Aged. Aged, 80 and over. Carcinoma, Adenoid Cystic / pathology. Diagnosis, Differential. Female. History, 16th Century. Humans. Immunohistochemistry. Inclusion Bodies / pathology. Male. Microscopy, Electron, Transmission. Middle Aged. Neoplasm Recurrence, Local / pathology. Neoplasm Recurrence, Local / ultrastructure. Neoplasms, Adnexal and Skin Appendage / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15900121.001).
  • [ISSN] 0193-1091
  • [Journal-full-title] The American Journal of dermatopathology
  • [ISO-abbreviation] Am J Dermatopathol
  • [Language] eng
  • [Publication-type] Historical Article; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


6. Benarroch-Gampel J, Riall TS: Extrapancreatic malignancies and intraductal papillary mucinous neoplasms of the pancreas. World J Gastrointest Surg; 2010 Oct 27;2(10):363-7

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The majority of these additional cancers occur before or concurrent with the diagnosis of IPMN.
  • The gastrointestinal tract is most commonly involved in secondary malignancies, with benign colon polyps and colon cancer commonly seen in western countries and gastric cancer commonly seen in Asian countries.
  • Other extrapancreatic malignancies associated with IPMNs include benign and malignant esophageal neoplasms, gastrointestinal stromal tumors, carcinoid tumors, hepatobiliary cancers, breast cancers, prostate cancers, and lung cancers.
  • Routine screening studies (breast and prostate) should be carried out as currently recommended for patient's age both before and after the diagnosis of IPMN.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21160845.001).
  • [ISSN] 1948-9366
  • [Journal-full-title] World journal of gastrointestinal surgery
  • [ISO-abbreviation] World J Gastrointest Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  • [Other-IDs] NLM/ PMC2999205
  • [Keywords] NOTNLM ; Intraductal papillary mucinous neoplasm / Invasive / Malignant potential / Non-invasive / Secondary malignancy
  •  go-up   go-down


7. Chen F, Sato T, Fujinaga T, Sakai H, Miyahara R, Bando T, Date H: Surgical management of bronchopulmonary typical carcinoid tumors: an institutional experience. Interact Cardiovasc Thorac Surg; 2010 Dec;11(6):737-9
MedlinePlus Health Information. consumer health - Carcinoid Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surgical management of bronchopulmonary typical carcinoid tumors: an institutional experience.
  • Bronchopulmonary typical carcinoid tumors are well known as low-grade malignant tumors with fairly benign behaviors; however, distant metastasis after complete resection and multiple carcinoid tumors in the resected lungs have been sporadically reported.
  • For better understanding of bronchopulmonary typical carcinoid tumors, we reviewed our institutional experience.
  • Eight patients with bronchopulmonary typical carcinoid tumors underwent complete pulmonary resection.
  • In one patient who received a lobectomy for a peripheral nodule, multiple carcinoid tumors were found in the resected specimen.
  • In one patient, tumors recurred at the bronchial stump and in the liver approximately five years after complete pulmonary resection.
  • Despite a small number of cases, our study supported the idea that bronchopulmonary typical carcinoid tumors might require major surgical procedures and that complete pulmonary resection of typical carcinoid tumors could expect long-term survival.
  • [MeSH-major] Bronchial Neoplasms / surgery. Carcinoid Tumor / surgery. Pneumonectomy
  • [MeSH-minor] Adult. Aged. Biopsy. Bronchoscopy. Female. Humans. Japan. Liver Neoplasms / secondary. Lymph Node Excision. Male. Middle Aged. Neoplasm Recurrence, Local. Retrospective Studies. Time Factors. Tomography, X-Ray Computed. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20852330.001).
  • [ISSN] 1569-9285
  • [Journal-full-title] Interactive cardiovascular and thoracic surgery
  • [ISO-abbreviation] Interact Cardiovasc Thorac Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


8. Modlin IM, Kidd M, Latich I, Zikusoka MN, Eick GN, Mane SM, Camp RL: Genetic differentiation of appendiceal tumor malignancy: a guide for the perplexed. Ann Surg; 2006 Jul;244(1):52-60
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Genetic differentiation of appendiceal tumor malignancy: a guide for the perplexed.
  • OBJECTIVE: To use differential gene expression of candidate markers to discriminate benign appendiceal carcinoids (APCs) from malignant and mixed cell APCs.
  • SUMMARY BACKGROUND DATA: Controversy exists in regard to the appropriate surgical management of APCs since it is sometimes difficult to predict tumor behavior using traditional pathologic criteria.
  • METHODS: Total RNA was isolated using TRIzol reagent from 42 appendiceal samples, including appendiceal carcinoids identified at exploration for appendicitis (no evidence of metastasis; n = 16), appendicitis specimens (n = 11), malignant appendiceal tumors (> 1.5 cm, evidence of metastatic invasion; n = 7), and mixed (goblet) cell appendiceal adenocarcinoids (n = 3), normal appendiceal tissue (n = 5), and 5 colorectal cancers.
  • RESULTS: CgA message was elevated (> 1000-fold, P < 0.05) in all tumor types.
  • MAGE-D2 and MTA1 message were significantly elevated (> 10-fold, P < 0.01) in the malignant and goblet cell adenocarcinoid tumors but not in the appendicitis-associated carcinoids or normal mucosa.
  • Elevated CgA transcript and protein levels indicative of a carcinoid tumor were identified in one acute appendicitis sample with no histologic evidence of a tumor.
  • CgA identified all appendiceal tumors as well as covert lesions, which may be more prevalent than previously recognized.
  • The molecular delineation of malignant appendiceal tumor potential provides a scientific basis to define the appropriate surgical management as opposed to morphologic assessment alone.

  • MedlinePlus Health Information. consumer health - Carcinoid Tumors.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Arch Intern Med. 1999 Sep 13;159(16):1841-5 [10493314.001]
  • [Cites] Am J Gastroenterol. 1998 Mar;93(3):422-8 [9517651.001]
  • [Cites] Cancer. 2005 Jan 15;103(2):229-36 [15599934.001]
  • [Cites] Gastroenterology. 2005 May;128(6):1717-51 [15887161.001]
  • [Cites] Ann Surg. 2006 Feb;243(2):273-80 [16432362.001]
  • [Cites] Ann Surg Oncol. 2006 Feb;13(2):253-62 [16424981.001]
  • [Cites] Cancer. 2006 Apr 1;106(7):1480-8 [16502410.001]
  • [Cites] Digestion. 2000;62 Suppl 1:33-8 [10940685.001]
  • [Cites] Am J Pathol. 2001 Feb;158(2):419-29 [11159180.001]
  • [Cites] J Clin Pathol. 2001 Apr;54(4):257-71 [11304841.001]
  • [Cites] Cancer. 2002 Mar 15;94(6):1821-9 [11920546.001]
  • [Cites] Mod Pathol. 2002 Jun;15(6):599-605 [12065772.001]
  • [Cites] Cancer. 2002 Jun 15;94(12):3307-12 [12115365.001]
  • [Cites] Am J Surg Pathol. 2002 Jul;26(7):863-72 [12131153.001]
  • [Cites] Nat Med. 2002 Nov;8(11):1323-7 [12389040.001]
  • [Cites] Pathol Oncol Res. 2002;8(3):204-19 [12516003.001]
  • [Cites] Cancer. 2003 Feb 15;97(4):934-59 [12569593.001]
  • [Cites] Exp Mol Pathol. 2003 Jun;74(3):336-40 [12782023.001]
  • [Cites] Eur J Surg Oncol. 2003 Oct;29(8):682-8 [14511618.001]
  • [Cites] Surg Oncol Clin N Am. 2003 Jul;12(3):585-603 [14567019.001]
  • [Cites] Br J Surg. 2003 Nov;90(11):1317-22 [14598408.001]
  • [Cites] Mod Pathol. 2003 Dec;16(12):1189-98 [14681318.001]
  • [Cites] Acta Oncol. 2003;42(7):672-92 [14690153.001]
  • [Cites] Biotechnol Bioeng. 2003 Dec 30;84(7):822-33 [14708123.001]
  • [Cites] Int J Oncol. 2004 Feb;24(2):305-12 [14719106.001]
  • [Cites] Dis Colon Rectum. 2004 Feb;47(2):163-9 [15043285.001]
  • [Cites] Int J Cancer. 2004 Jun 20;110(3):362-7 [15095300.001]
  • [Cites] Hum Pathol. 2004 Apr;35(4):424-9 [15116322.001]
  • [Cites] Am Surg. 2004 Jul;70(7):593-9 [15279181.001]
  • [Cites] Surg Endosc. 2004 Jul;18(7):1063-6 [15156378.001]
  • [Cites] Digestion. 1986;35 Suppl 1:3-22 [3539679.001]
  • [Cites] Acta Oncol. 1989;28(3):325-9 [2545231.001]
  • [Cites] N Engl J Med. 1992 Oct 29;327(18):1285-8 [1406819.001]
  • [Cites] Biochem J. 1994 Jan 15;297 ( Pt 2):389-97 [8297347.001]
  • [Cites] J Biol Chem. 1994 Sep 16;269(37):22958-63 [8083195.001]
  • [Cites] Gene. 1995 Jun 14;159(1):97-104 [7607577.001]
  • [Cites] Int J Cancer. 1997 Aug 22;74(4):459-63 [9291440.001]
  • [Cites] Dis Colon Rectum. 1998 Jan;41(1):75-80 [9510314.001]
  • [Cites] Appl Immunohistochem Mol Morphol. 2004 Sep;12(3):266-70 [15551742.001]
  • (PMID = 16794389.001).
  • [ISSN] 0003-4932
  • [Journal-full-title] Annals of surgery
  • [ISO-abbreviation] Ann. Surg.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA097050; United States / NCI NIH HHS / CA / R01-CA-097050
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adaptor Proteins, Signal Transducing; 0 / Antigens, Neoplasm; 0 / Apoptosis Regulatory Proteins; 0 / Biomarkers, Tumor; 0 / Cell Cycle Proteins; 0 / Chromogranin A; 0 / Chromogranins; 0 / Genetic Markers; 0 / MAGED2 protein, human; 0 / NAP1L1 protein, human; 0 / NLRP1 protein, human; 0 / Nuclear Proteins; 0 / Nucleosome Assembly Protein 1; 0 / Repressor Proteins; EC 3.5.1.- / Mta1 protein, human; EC 3.5.1.98 / Histone Deacetylases
  • [Other-IDs] NLM/ PMC1570599
  •  go-up   go-down


9. Basic-Jukic N, Furic-Cunko V, Coric M, Bubic-Filipi LJ, Kastelan Z, Pasini J, Kes P: Appendiceal carcinoid and mucinous cystadenoma in renal transplant recipients: case reports. Transplant Proc; 2010 Jun;42(5):1704-7
MedlinePlus Health Information. consumer health - Kidney Transplantation.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Appendiceal carcinoid and mucinous cystadenoma in renal transplant recipients: case reports.
  • There is an increased incidence of tumors among renal transplant patients, which are associated with immunosuppression.
  • Carcinoids are rare neuroendocrine tumors that arise from the enterochromaffin cells.
  • Although appendiceal carcinoid tumors are the commonest malignant neoplasms affecting the appendix, and mucinous cystadenoma is the commonest benign appendiceal neoplasm, they have not been reported in immunosuppressed patients.
  • We present two renal transplant recipients who developed combined appendiceal carcinoid and mucinous cystadenoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20620505.001).
  • [ISSN] 1873-2623
  • [Journal-full-title] Transplantation proceedings
  • [ISO-abbreviation] Transplant. Proc.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


10. Das-Neves-Pereira JC, de Matos LL, Danel C, Trufelli D, Riquet M: Typical bronchopulmonary carcinoid tumors: a ramifying bronchial presentation with metastatic behavior. Ann Thorac Surg; 2006 Dec;82(6):2265-6
MedlinePlus Health Information. consumer health - Carcinoid Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Typical bronchopulmonary carcinoid tumors: a ramifying bronchial presentation with metastatic behavior.
  • Bronchopulmonary typical carcinoid tumors (BTCT) are neuroendocrine neoplasms with histologic low grade characteristics considered benign.
  • Metastasis occurred despite typical carcinoid microscopic features in 3 female patients of African origin presenting at macroscopic examination as ramifying bronchopulmonary typical carcinoid tumors following the bronchial tree.
  • We suggest that clinical ramifying presentation may be related to metastatic behavior, even for bronchopulmonary typical carcinoid tumors not displaying histologic criteria for atypical carcinoid tumors.
  • [MeSH-major] Bronchial Neoplasms / pathology. Carcinoid Tumor / pathology
  • [MeSH-minor] Aged. Female. Humans. Neoplasm Metastasis. Pneumonectomy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17126146.001).
  • [ISSN] 1552-6259
  • [Journal-full-title] The Annals of thoracic surgery
  • [ISO-abbreviation] Ann. Thorac. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


11. Capovilla M, Kambouchner M, Bernier M, Soulier A, Tissier F, Saintigny P: Late cerebellar relapse of a juvenile bronchial carcinoid. Clin Lung Cancer; 2007 Mar;8(5):339-41
MedlinePlus Health Information. consumer health - Carcinoid Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Late cerebellar relapse of a juvenile bronchial carcinoid.
  • Although epithelial bronchial neoplasm is a cancer frequently observed in adult patients, it is rarely observed in patients who are children.
  • The most frequent histologic subtype is well differentiated neuroendocrine tumor, or carcinoid.
  • They have a variable biologic behavior, ranging from benign to malignant tumors capable of very late recurrence or metastasis.
  • Liver and lung are frequent sites of carcinoid metastasis, and the central nervous system is exceptionally involved.
  • We report the case of a child with a pulmonary carcinoid initially considered typical, who presented with relapse in the cerebellum and mediastinum 16 years later.
  • After review of the pathology slides, primary and metastatic tumors were reclassified as atypical carcinoid according to the criteria of the 2004 World Health Organization classification of lung tumors.
  • [MeSH-major] Bronchial Neoplasms / pathology. Carcinoid Tumor / pathology. Cerebellar Neoplasms / diagnosis. Cerebellar Neoplasms / secondary. Neoplasm Recurrence, Local / diagnosis. Neoplasm Recurrence, Local / secondary

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17562235.001).
  • [ISSN] 1525-7304
  • [Journal-full-title] Clinical lung cancer
  • [ISO-abbreviation] Clin Lung Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


12. De Dosso S, Bajetta E, Procopio G, Cortinovis D, Buzzoni R, Catena L, Platania M, Verzoni E: Pulmonary carcinoid tumours: indolent but not benign. Oncology; 2007;73(3-4):162-8
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pulmonary carcinoid tumours: indolent but not benign.
  • RESULTS: At diagnosis, there were 37 metastatic and 11 non-metastatic patients.
  • [MeSH-major] Carcinoid Tumor / pathology. Lung Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Disease Progression. Disease-Free Survival. Female. Humans. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Recurrence, Local / diagnosis. Neoplasm Staging. Prognosis. Retrospective Studies. Survival Rate

  • MedlinePlus Health Information. consumer health - Carcinoid Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2008 S. Karger AG, Basel
  • (PMID = 18418008.001).
  • [ISSN] 1423-0232
  • [Journal-full-title] Oncology
  • [ISO-abbreviation] Oncology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


13. Strehl MA, Scheich M, Ott I, Müller-Hermelink HK, Hagen R, Völker HU: [Middle ear adenoma/middle ear carcinoid--an unproblematic tumor?]. Laryngorhinootologie; 2009 Mar;88(3):186-90
MedlinePlus Health Information. consumer health - Carcinoid Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Middle ear adenoma/middle ear carcinoid--an unproblematic tumor?].
  • [Transliterated title] Mittelohradenom/Mittelohrkarzinoid--ein unproblematischer Tumor?
  • OBJECTIVES: Adenomas/carcinoid tumors of the middle ear are very rare tumors of young to middle aged patients.
  • The terms adenoma and carcinoid tumor of the middle ear can be used as synonyms, with the WHO favouring the term middle ear adenoma (MEA).
  • These tumors usually present with unspecific clinical symptoms and a long case history.
  • They are classified as benign tumors with only very few reported cases of regional metastasis after years of disease.
  • METHODS AND PATIENTS: This study describes the clinical course and the diagnostic challenges in four cases of this rare tumor entity.
  • In two cases a tumor recurrence was documented with one case recurring six times.
  • The histological differential diagnosis can also be problematic; in one case with a highly atypical morphology it was impossible to arrive at a definite diagnosis during the analysis of a frozen section.
  • The presented cases in this study and the analysis of previously published cases shows that the typical progression described by the current WHO-classification with unproblematic surgical management of the tumor and an uncomplicated further clinical course does not always correspond to reality.
  • [MeSH-major] Adenoma / diagnosis. Carcinoid Tumor / diagnosis. Ear Neoplasms / diagnosis. Ear, Middle
  • [MeSH-minor] Adult. Cholesteatoma, Middle Ear / diagnosis. Cholesteatoma, Middle Ear / pathology. Cholesteatoma, Middle Ear / surgery. Diagnosis, Differential. Female. Humans. Magnetic Resonance Imaging. Male. Neoplasm Recurrence, Local / surgery. Otoscopy. Reoperation. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Carcinoid Tumor.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19065497.001).
  • [ISSN] 0935-8943
  • [Journal-full-title] Laryngo- rhino- otologie
  • [ISO-abbreviation] Laryngorhinootologie
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


14. Choi US, Alleman AR, Choi JH, Kim HW, Youn HJ, Lee CW: Cytologic and immunohistochemical characterization of a lung carcinoid in a dog. Vet Clin Pathol; 2008 Jun;37(2):249-52
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytologic and immunohistochemical characterization of a lung carcinoid in a dog.
  • Cells were arranged in packets separated by fine fibrovascular stroma, suggestive of a pulmonary neuroendocrine neoplasm, specifically a carcinoma/carcinoid.
  • With these findings the tumor was diagnosed as a primary lung carcinoid.
  • Eleven months after resection, there was no evidence of tumor regrowth or metastasis.
  • The absence of necrosis, few mitotic figures, minimal pleomorphism, and benign behavior of this tumor resembled those of a typical carcinoid in humans.

  • MedlinePlus Health Information. consumer health - Carcinoid Tumors.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18533928.001).
  • [ISSN] 0275-6382
  • [Journal-full-title] Veterinary clinical pathology
  • [ISO-abbreviation] Vet Clin Pathol
  • [Language] ENG
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


15. Ferlito A, Devaney KO, Rinaldo A: Primary carcinoid tumor of the middle ear: a potentially metastasizing tumor. Acta Otolaryngol; 2006 Mar;126(3):228-31
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary carcinoid tumor of the middle ear: a potentially metastasizing tumor.
  • The concept of a carcinoid tumor in the gastrointestinal tract and lung is well established; less often, patients develop carcinoid tumors in the head and neck region.
  • One particularly uncommon site of origin of carcinoid tumors in the head and neck area is the middle ear.
  • Middle ear carcinoids have previously been approached as benign entities, lacking any capacity for metastasizing.
  • A critical review of the literature, however, disclosed a small number of cases in which middle ear carcinoid tumors have given rise to regional (cervical node) metastases.
  • This in turn suggests that, as is the case with pulmonary carcinoid tumors, middle ear carcinoids should be thought of as low-grade malignancies which, while relatively slow-growing, nevertheless possess a limited capacity for spreading to regional lymph nodes.
  • To date, distant metastases have not been associated with middle ear carcinoid tumors.
  • [MeSH-major] Carcinoid Tumor / secondary. Ear Neoplasms / pathology. Ear, Middle. Lymphatic Metastasis / pathology. Neoplasm Invasiveness / pathology
  • [MeSH-minor] Biopsy, Needle. Female. Humans. Immunohistochemistry. Male. Neoplasm Staging. Prognosis. Risk Assessment. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Carcinoid Tumor.
  • MedlinePlus Health Information. consumer health - Carcinoid Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16618645.001).
  • [ISSN] 0001-6489
  • [Journal-full-title] Acta oto-laryngologica
  • [ISO-abbreviation] Acta Otolaryngol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Review
  • [Publication-country] Norway
  • [Number-of-references] 21
  •  go-up   go-down


16. Clemente G, Sarno G, Giordano M, De Rose AM, Giovannini I, Vecchio FM, Nuzzo G: Total gastrectomy for type 1 gastric carcinoid: an unusual surgical indication? Minerva Chir; 2007 Oct;62(5):421-4
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Total gastrectomy for type 1 gastric carcinoid: an unusual surgical indication?
  • Gastric carcinoid is a relatively rare neoplasm with peculiar features which differentiate it from the intestinal and pulmonary carcinoid and, obviously, from gastric adenocarcinoma.
  • Gastric carcinoids are divided into three different types: Type 1, associated with gastric atrophy and megaloblastic anemia; Type 2, associated with Zollinger-Ellison syndrome within a type 1 multiple endocrine neoplasia (MEN); and Type 3, sporadic tumor not associated with other lesions, particularly invasive and with poor prognosis.
  • Type 1 carcinoid is usually asymptomatic and casually detected at endoscopy due to aspecific symptoms or to screening in patients with atrophic gastritis.
  • It is generally small, multifocal and located in the gastric fundus, has no tendency for vascular invasion and is associated with a benign course.
  • We report a case of a woman with a type 1 gastric carcinoid in which, for the presence of an extended micro-polyposis of the fundus a total gastrectomy was necessary for treatment.
  • In conclusion this finding, unknown before surgery, emphasizes the need for careful assessment also in the presence of apparently less important gastric carcinoid lesions.
  • [MeSH-major] Carcinoid Tumor / surgery. Gastrectomy. Stomach Neoplasms / pathology. Stomach Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Carcinoid Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17947953.001).
  • [ISSN] 0026-4733
  • [Journal-full-title] Minerva chirurgica
  • [ISO-abbreviation] Minerva Chir
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


17. Cañizares MA, García-Fontán EM, Rivo JE, Gonzalez-Piñeiro A: Local recurrence and metastatic disease in a typical N1 carcinoid bronchial tumour. Clin Transl Oncol; 2005 Jun;7(5):216-8
MedlinePlus Health Information. consumer health - Carcinoid Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Local recurrence and metastatic disease in a typical N1 carcinoid bronchial tumour.
  • Typical carcinoid bronchial tumour is a well-known disease that, for years, was considered benign.
  • We present, here, a case of a 19-years-old female diagnosed as having N1-bronchial typical carcinoid tumour.
  • [MeSH-major] Bronchial Neoplasms / pathology. Carcinoid Tumor / pathology. Neoplasm Recurrence, Local / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Neoplasma. 2003;50(1):60-5 [12687280.001]
  • [Cites] Endocr Relat Cancer. 2003 Dec;10(4):463-8 [14713259.001]
  • [Cites] J Thorac Cardiovasc Surg. 1994 Jan;107(1):1-6; discussion 6-7 [8283871.001]
  • [Cites] J Thorac Cardiovasc Surg. 2002 Feb;123(2):303-9 [11828290.001]
  • [Cites] Arch Bronconeumol. 1998 Feb;34(2):71-5 [9557178.001]
  • [Cites] Lung Cancer. 2004 Jan;43(1):39-45 [14698535.001]
  • [Cites] Clin Endocrinol (Oxf). 2003 Dec;59(6):793-9 [14974924.001]
  • [Cites] Ann Thorac Surg. 2003 Dec;76(6):1838-42 [14667595.001]
  • [Cites] Hepatogastroenterology. 1999 Sep-Oct;46(29):2961-4 [10576382.001]
  • [Cites] Eur J Cardiothorac Surg. 2000 Sep;18(3):301-6 [10973539.001]
  • [Cites] Ann Thorac Surg. 2000 Jul;70(1):258-63 [10921719.001]
  • [Cites] J Gastrointest Surg. 2004 Feb;8(2):208-12 [15036197.001]
  • [Cites] Am J Surg. 2004 Jan;187(1):39-46 [14706584.001]
  • (PMID = 15960934.001).
  • [ISSN] 1699-048X
  • [Journal-full-title] Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
  • [ISO-abbreviation] Clin Transl Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


18. Reid-Lombardo KM, Mathis KL, Wood CM, Harmsen WS, Sarr MG: Frequency of extrapancreatic neoplasms in intraductal papillary mucinous neoplasm of the pancreas: implications for management. Ann Surg; 2010 Jan;251(1):64-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Frequency of extrapancreatic neoplasms in intraductal papillary mucinous neoplasm of the pancreas: implications for management.
  • Two control groups consisting of Group 1-patients with a diagnosis of ductal pancreatic adenocarcinoma (1:1) and Group 2-a general referral population (3:1) were matched for gender and age at diagnosis, year of registration, and residence.
  • Logistic regression was used to assess the risk of a diagnosis of extrapancreatic neoplasms among cases versus controls.
  • The proportion of IPMN patients having any extrapancreatic neoplasm diagnosed before or coincident to the index date was 52% (95% CI, 47%-56%), compared with 36% (95% CI, 32%-41%) in Group 1 (P < 0.001), and 43% (95% CI, 41%-46%) in Group 2 (P = 0.002).
  • Benign neoplasms most frequent in the IPMN group were colonic polyps (n = 114) and Barrett's neoplasia (n = 18).
  • The most common malignant neoplasms were nonmelanoma skin (n = 35), breast (n = 24), prostate (n = 24), colorectal cancers (n = 19), and carcinoid neoplasms (n = 6).
  • [MeSH-major] Adenocarcinoma, Mucinous / therapy. Carcinoma, Pancreatic Ductal / therapy. Carcinoma, Papillary / therapy. Neoplasms, Multiple Primary / diagnosis. Pancreatic Neoplasms / therapy

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19858708.001).
  • [ISSN] 1528-1140
  • [Journal-full-title] Annals of surgery
  • [ISO-abbreviation] Ann. Surg.
  • [Language] eng
  • [Grant] United States / NCRR NIH HHS / RR / 1 UL1 RR024150
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  •  go-up   go-down


19. Seemann MD, Meisetschlaeger G, Gaa J, Rummeny EJ: Assessment of the extent of metastases of gastrointestinal carcinoid tumors using whole-body PET, CT, MRI, PET/CT and PET/MRI. Eur J Med Res; 2006 Feb 21;11(2):58-65
MedlinePlus Health Information. consumer health - MRI Scans.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Assessment of the extent of metastases of gastrointestinal carcinoid tumors using whole-body PET, CT, MRI, PET/CT and PET/MRI.
  • OBJECTIVE: To assess the diagnostic value of whole-body positron emission tomography (PET), computed tomography (CT), magnetic resonance imaging (MRI), and the fusion of PET and CT (PET/CT) and PET and MRI (PET/MRI) in the detection of metastatic disease of gastrointestinal carcinoid tumors.
  • MATERIALS AND METHODS: This prospective study included six patients with extensive nonresectable metastases of gastrointestinal carcinoid tumors which were consecutively examined from the base of the skull to the proximal thigh using a state-of-the-art PET/CT scanner and a 1.5 Tesla whole-body MRI scanner.
  • Lesions were rated as metastases if they were not clearly identified as benign lesions according to standard radiological criteria.
  • [MeSH-major] Carcinoid Tumor / pathology. Gastrointestinal Neoplasms / pathology. Magnetic Resonance Imaging. Neoplasm Metastasis. Positron-Emission Tomography. Tomography, X-Ray Computed. Whole Body Imaging
  • [MeSH-minor] Aged. Female. Humans. Image Processing, Computer-Assisted. Male. Middle Aged. Neoplasm Staging. Prospective Studies

  • MedlinePlus Health Information. consumer health - Carcinoid Tumors.
  • MedlinePlus Health Information. consumer health - CT Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16504962.001).
  • [ISSN] 0949-2321
  • [Journal-full-title] European journal of medical research
  • [ISO-abbreviation] Eur. J. Med. Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


20. Jungraithmayr W, Eggeling S, Ludwig C, Kayser G, Passlick B: Sclerosing hemangioma of the lung: a benign tumour with potential for malignancy? Ann Thorac Cardiovasc Surg; 2006 Oct;12(5):352-4
Genetic Alliance. consumer health - Hemangioma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sclerosing hemangioma of the lung: a benign tumour with potential for malignancy?
  • Pulmonary sclerosing hemangioma represents a rare neoplasm with variable potential for progression.
  • Intraoperative findings were suggestive of a carcinoid tumour.
  • The histopathological analysis revealed a sclerosing hemangioma, a rare benign neoplasm.
  • Generally, wedge resection is justified in the majority of cases, but in cases of uncertain intraoperative diagnosis, anatomic resection with systematic lymphadenectomy is recommended.
  • [MeSH-major] Pneumonectomy / methods. Pulmonary Sclerosing Hemangioma / diagnosis
  • [MeSH-minor] Adult. Bronchoscopy. Diagnosis, Differential. Female. Humans. Lung Neoplasms / diagnosis. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17095978.001).
  • [ISSN] 1341-1098
  • [Journal-full-title] Annals of thoracic and cardiovascular surgery : official journal of the Association of Thoracic and Cardiovascular Surgeons of Asia
  • [ISO-abbreviation] Ann Thorac Cardiovasc Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


21. Jiang X, Dong X, Zhao X, Peng C: Bronchial sleeve resection distal to the main bronchus with complete pulmonary preservation for benign or low-grade malignant tumors. Ann Thorac Surg; 2007 Oct;84(4):e19-21

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bronchial sleeve resection distal to the main bronchus with complete pulmonary preservation for benign or low-grade malignant tumors.
  • Three cases are presented with benign or low-grade malignant bronchial tumors managed by bronchial sleeve resection distal to the main bronchus.
  • Bronchial sleeve resection distal to the main bronchus can be successfully performed; this is a safe and effective bronchoplastic technique for benign or low-grade malignant bronchial tumors.
  • [MeSH-minor] Adult. Bronchoscopy / methods. Carcinoid Tumor / pathology. Carcinoid Tumor / surgery. Female. Follow-Up Studies. Granuloma, Plasma Cell / pathology. Granuloma, Plasma Cell / surgery. Humans. Immunohistochemistry. Leiomyoma / pathology. Leiomyoma / radiography. Leiomyoma / surgery. Male. Middle Aged. Neoplasm Staging. Risk Assessment. Tomography, X-Ray Computed. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17888950.001).
  • [ISSN] 1552-6259
  • [Journal-full-title] The Annals of thoracic surgery
  • [ISO-abbreviation] Ann. Thorac. Surg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


22. Cunningham JL, Grimelius L, Sundin A, Agarwal S, Janson ET: Malignant ileocaecal serotonin-producing carcinoid tumours: the presence of a solid growth pattern and/or Ki67 index above 1% identifies patients with a poorer prognosis. Acta Oncol; 2007;46(6):747-56
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant ileocaecal serotonin-producing carcinoid tumours: the presence of a solid growth pattern and/or Ki67 index above 1% identifies patients with a poorer prognosis.
  • Patients with malignant serotonin-producing carcinoid tumours in the jejunum, ileum and caecum generally have long survival expectancy.
  • This study also showed that Ki67 index <2% cannot, as previously suggested, be used to indicate a benign progression for this tumour category.
  • [MeSH-major] Biomarkers, Tumor / analysis. Carcinoid Tumor / physiopathology. Cecal Neoplasms / physiopathology. Ileal Neoplasms / physiopathology. Ki-67 Antigen / analysis. Serotonin / biosynthesis
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Apoptosis. Disease Progression. Female. Health Status Indicators. Humans. Male. Middle Aged. Neoplasm Staging. Prognosis. Retrospective Studies. Survival. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Carcinoid Tumors.
  • MedlinePlus Health Information. consumer health - Intestinal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17653896.001).
  • [ISSN] 0284-186X
  • [Journal-full-title] Acta oncologica (Stockholm, Sweden)
  • [ISO-abbreviation] Acta Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Norway
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Ki-67 Antigen; 333DO1RDJY / Serotonin
  •  go-up   go-down


23. Valdes EK, Feldman SM, Krassilnik N: Neuroendocrine tumor of the breast. Am Surg; 2006 Feb;72(2):185-7
MedlinePlus Health Information. consumer health - Carcinoid Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neuroendocrine tumor of the breast.
  • Mammary carcinoid is an uncommon neoplasm.
  • However, it is still controversial whether mammary carcinoid tumors should be considered a distinct clinical entity or be treated as a variant of conventional breast carcinoma.
  • Differentiating these lesions from benign lesions such as epithelial hyperplasia and papillomas can be challenging at times.
  • We present a case of neuroendocrine tumor of the breast.
  • [MeSH-major] Breast Neoplasms / pathology. Carcinoid Tumor / pathology. Carcinoma, Ductal, Breast / pathology

  • Genetic Alliance. consumer health - Pancreatic islet cell tumors.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16536254.001).
  • [ISSN] 0003-1348
  • [Journal-full-title] The American surgeon
  • [ISO-abbreviation] Am Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


24. Alsaad KO, Serra S, Schmitt A, Perren A, Chetty R: Cytokeratins 7 and 20 immunoexpression profile in goblet cell and classical carcinoids of appendix. Endocr Pathol; 2007;18(1):16-22
MedlinePlus Health Information. consumer health - Carcinoid Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Goblet cell carcinoid (GCC) of the vermiform appendix is an uncommon neoplasm and its histogenesis is controversial.
  • Whether GCC represents a morphological variant of classical appendiceal carcinoid or a mucin-producing adenocarcinoma is still conjectural.
  • Little is known about the immunohistochemical expression of cytokeratins 7 (CK7) and 20 (CK20) in appendiceal neuroendocrine tumors.
  • In this study, we compared the expression of CK7 and CK20 in 17 cases of appendiceal GCC and 25 cases of classical carcinoid.
  • The tumors were also evaluated for Ki-67 proliferation index, mitotic activity, tumor necrosis, extracellular pools of mucin, obvious intestinal type adenocarcinomatous foci, angiolymphatic permeation, perineural/neural infiltration, and the depth of invasion of the appendix wall.
  • Immunohistochemically, all 17 (100%) of GCC exhibited strong and diffuse immunopositivity for CK20, whereas expression of CK7 was present in 12 cases (70.5%), ranging from 5 to 50% of tumor cells being labeled.
  • On the other hand, 25 cases of classical carcinoid tumors were consistently negative for CK7; however, 4 cases (16%) showed immunolabeling for CK20 in 25-50% of the tumor cells.
  • This study shows that in addition to the morphological differences, GCC (CK7/CK20-positive) and classical carcinoid (CK7/CK20-negative) differ in their expression of CK7 and CK20.
  • Goblet cell carcinoid should be regarded as a crypt cell or an amphicrine carcinoma rather than a variant of carcinoid tumor, a lesion that has benign connotations.
  • [MeSH-major] Appendiceal Neoplasms / metabolism. Carcinoid Tumor / metabolism. Goblet Cells / metabolism. Keratin-20 / metabolism. Keratin-7 / metabolism
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / metabolism. Cell Proliferation. Female. Humans. Immunohistochemistry. Ki-67 Antigen / metabolism. Male. Middle Aged. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Surg Pathol. 1982 Mar;6(2):188-9 [7102895.001]
  • [Cites] Br J Surg. 2003 Nov;90(11):1317-22 [14598408.001]
  • [Cites] Differentiation. 1993 Jun;53(2):75-93 [8359595.001]
  • [Cites] Ann N Y Acad Sci. 2004 Apr;1014:13-27 [15153416.001]
  • [Cites] Mod Pathol. 2003 Dec;16(12):1189-98 [14681318.001]
  • [Cites] Endocr Pathol. 2002 Spring;13(1):47-58 [12114750.001]
  • [Cites] World J Surg Oncol. 2005 Jun 20;3:36 [15967038.001]
  • [Cites] Am J Surg Pathol. 1981 Apr;5(3):213-24 [7235117.001]
  • [Cites] Best Pract Res Clin Gastroenterol. 2005 Oct;19(5):729-38 [16253897.001]
  • [Cites] Am J Surg. 1994 Dec;168(6):685-7 [7978019.001]
  • [Cites] Am Surg. 2004 Jul;70(7):593-9 [15279181.001]
  • [Cites] Histopathology. 1992 Apr;20(4):345-9 [1577412.001]
  • [Cites] Histopathology. 2003 Feb;42(2):137-40 [12558745.001]
  • [Cites] Eur J Surg Oncol. 1992 Aug;18(4):386-7 [1521632.001]
  • [Cites] Ann Surg Oncol. 2006 Mar;13(3):370-6 [16485156.001]
  • [Cites] Surg Today. 2000;30(1):78-81 [10648090.001]
  • [Cites] Cancer. 1979 Nov;44(5):1700-6 [498041.001]
  • [Cites] Ann Anat Pathol (Paris). 1969 Oct-Dec;14(4):393-406 [5378353.001]
  • [Cites] J Clin Pathol. 1995 Sep;48(9):869-70 [7490325.001]
  • [Cites] Cancer. 1974 Aug;34(2):338-44 [4852178.001]
  • [Cites] Arch Pathol Lab Med. 2001 Mar;125(3):386-90 [11231488.001]
  • [Cites] Pathol Int. 2005 Aug;55(8):524-9 [15998383.001]
  • [Cites] Cancer. 1999 Jul 1;86(1):14-21 [10391558.001]
  • [Cites] Appl Immunohistochem Mol Morphol. 2004 Sep;12(3):271-6 [15551743.001]
  • (PMID = 17652796.001).
  • [ISSN] 1046-3976
  • [Journal-full-title] Endocrine pathology
  • [ISO-abbreviation] Endocr. Pathol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Keratin-20; 0 / Keratin-7; 0 / Ki-67 Antigen
  •  go-up   go-down


25. Kapur U, Helenowski M, Zayaad A, Ghai R, Vigeneswaran W, Rajan P: Pulmonary glomus tumor. Ann Diagn Pathol; 2007 Dec;11(6):457-9
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pulmonary glomus tumor.
  • Glomus tumor (GT) is an infrequent but distinct neoplasm.
  • Pulmonary GT is a rare neoplasm with only a few cases reported in the literature.
  • These tumors are usually benign and, although rare, tumors with aggressive behavior have been reported.
  • The tumor size, location, and histomorphological features may be useful in predicting tumor behavior.
  • We present here a case of pulmonary GT that was initially diagnosed as a typical carcinoid tumor.
  • The differential diagnosis as well as the recent classification of GTs is discussed along with a review of literature.
  • [MeSH-major] Glomus Tumor / pathology. Lung Neoplasms / pathology
  • [MeSH-minor] Adult. Asthma / complications. Carcinoid Tumor / pathology. Diabetes Mellitus. Diagnosis, Differential. Humans. Hypertension / complications. Immunohistochemistry. Male. Obesity, Morbid / complications

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18022133.001).
  • [ISSN] 1092-9134
  • [Journal-full-title] Annals of diagnostic pathology
  • [ISO-abbreviation] Ann Diagn Pathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


26. Vallot T: [Gastric polyps]. Presse Med; 2007 Oct;36(10 Pt 2):1412-7
MedlinePlus Health Information. consumer health - Stomach Disorders.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Gastric polyps exist in a wide variety of types, most often benign.
  • Hyperplastic polyps, adenomas and tumors must be totally resected.
  • Carcinoid tumors of the fundus most often occur in patients with hypergastrinemia during atrophic gastritis of autoimmune origin; they are not serious.
  • [MeSH-major] Adenocarcinoma. Adenoma. Carcinoid Tumor. Polyps. Precancerous Conditions. Stomach Diseases. Stomach Neoplasms
  • [MeSH-minor] Aged. Biopsy. Diagnosis, Differential. Endoscopy. Helicobacter Infections / complications. Helicobacter Infections / prevention & control. Helicobacter pylori. Humans. Incidence. Lymphatic Metastasis. Neoplasm Metastasis. Prevalence. Risk Factors. Stomach / pathology

  • MedlinePlus Health Information. consumer health - Carcinoid Tumors.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17482791.001).
  • [ISSN] 0755-4982
  • [Journal-full-title] Presse medicale (Paris, France : 1983)
  • [ISO-abbreviation] Presse Med
  • [Language] fre
  • [Publication-type] Comparative Study; English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Number-of-references] 35
  •  go-up   go-down


27. Coco C, Rizzo G, Manno A, Mattana C, Verbo A: Surgical treatment of small bowel neoplasms. Eur Rev Med Pharmacol Sci; 2010 Apr;14(4):327-33

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Benign small intestinal tumors (e.g., leiomyoma, lipoma, hamartoma, or desmoid tumor) usually are asymptomatic but may present with complications.
  • Primary malignancies of the small intestine, including adenocarcinoma, leiomyosarcoma, carcinoid, and lymphoma, are often symptomatic and may present with intestinal obstruction, jaundice, bleeding, or pain.
  • Because the small intestine is relatively inaccessible to routine endoscopy, diagnosis of small intestinal neoplasms is often delayed for months after onset of symptoms.
  • During last years the increase of small bowel endoscopy and other diagnostic tools allow earlier non-operative diagnosis.
  • [MeSH-minor] Carcinoid Tumor / pathology. Carcinoid Tumor / surgery. Gastrointestinal Stromal Tumors / pathology. Gastrointestinal Stromal Tumors / surgery. Humans. Laparoscopy. Lymphoma / pathology. Lymphoma / surgery. Neoplasm Metastasis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20496543.001).
  • [ISSN] 1128-3602
  • [Journal-full-title] European review for medical and pharmacological sciences
  • [ISO-abbreviation] Eur Rev Med Pharmacol Sci
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Italy
  • [Number-of-references] 51
  •  go-up   go-down


28. Guillem JG, Chessin DB, Jeong SY, Kim W, Fogarty JM: Contemporary applications of transanal endoscopic microsurgery: technical innovations and limitations. Clin Colorectal Cancer; 2005 Nov;5(4):268-73
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: Transanal endoscopic microsurgery (TEM) is a minimally invasive procedure used to transanally excise select benign and malignant tumors of the rectum.
  • In addition, a PubMed literature search was performed with use of the key words "transanal endoscopic microsurgery," "TEM," "rectal tumor," and "rectal cancer."
  • RESULTS: Transanal endoscopic microsurgery was performed for rectal adenocarcinoma (n = 17; 53%), adenoma (n = 12; 38%), and carcinoid tumors (n = 3; 9%).
  • Median tumor location was 9 cm from the anal verge (range, 3-15 cm).
  • Reasons for inability to complete TEM included narrow rectal lumen or contour of bony pelvis prohibiting passage of the operating proctoscope into the upper rectum and inability to maintain the proctoscope in the rectal lumen with carbon dioxide insufflation because of the distal location of the tumor.
  • Innovations used in the excision of rectal tumors via TEM included the use of the harmonic scalpel, closure of the rectal defect with an extracorporeal slip knot, and a hybrid approach incorporating TEM and traditional transanal techniques.
  • [MeSH-major] Adenocarcinoma / surgery. Adenoma / surgery. Carcinoid Tumor / surgery. Colonoscopy / methods. Rectal Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Anal Canal. Female. Humans. Male. Microsurgery. Middle Aged. Neoplasm Staging. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Carcinoid Tumors.
  • MedlinePlus Health Information. consumer health - Colonoscopy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16356304.001).
  • [ISSN] 1533-0028
  • [Journal-full-title] Clinical colorectal cancer
  • [ISO-abbreviation] Clin Colorectal Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


29. Cheng NH, Huang HF, Lian LJ, Wu Y: [Ovarian growing teratoma syndrome clinical study of 22 cases]. Zhonghua Fu Chan Ke Za Zhi; 2009 Jun;44(6):426-30
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To describe the essential points for the correct diagnosis and best treatment for ovarian growing teratoma syndrome (GTS) developed after surgery and chemotherapy for ovarian immature teratoma.
  • METHODS: Retrospective review of the clinical characteristics and long term follow up results of 22 cases of ovarian GTS to illustrate the unique biological behavior of the tumor and good prognosis of the disease.
  • RESULTS: Pathological examination of the tumors revealed completely benign mature teratoma with G0 grading in 20 cases.
  • The other 2 cases were found to be G0 mature teratoma with concurrent association of malignant somatic cell tumor: carcinoid and primitive neuroectodermal tumor (PNET) respectively.
  • Among the 22 cases of ovarian GTS there are 6 cases with recurrent tumors developed repeatedly, so totally surgical treatments had been performed for 31 times.
  • Such a time factor is of high significance for the diagnosis of ovarian GTS.
  • As the benign behavior of the ovarian GTS together with its poor response to chemotherapy have just been recognized in recent years, they were treated as malignant tumors as their original primary immature teratoma before the year of 1987.
  • The rest 2 patients died of the concurrent association of malignant somatic cell tumors with carcinoid and PNET in 0.1 and 0.3 years respectively.
  • CONCLUSIONS: Ovarian GTS is a tumor developed after surgical and chemotherapeutic treatment of malignant ovarian immature teratoma.
  • Pathologic grading of the tumors showed retroconversion of the malignancy of the tumor from G3, G2 or G1 to G0 with good prognosis.
  • The tumor usually remained to be quiescent for long periods of time.
  • But there are also some potential of progressive growth, the tumor may grow to huge size and the recurrent tumor may develop repeatedly for several times more than 10 or 20 years later.
  • Surgical removal should be the main treatment either for the primary or the recurrent tumors.
  • Only correct knowledge about the benign biological behavior of the ovarian GTS and reasonable therapeutic regimen can have the disease ends with good prognosis.
  • [MeSH-minor] Adolescent. Adult. Carcinoid Tumor / secondary. Child. Female. Follow-Up Studies. Humans. Neoplasm Recurrence, Local / epidemiology. Neoplasm Recurrence, Local / pathology. Prognosis. Retrospective Studies. Syndrome. Treatment Outcome. Young Adult

  • Genetic Alliance. consumer health - Teratoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19953942.001).
  • [ISSN] 0529-567X
  • [Journal-full-title] Zhonghua fu chan ke za zhi
  • [ISO-abbreviation] Zhonghua Fu Chan Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


30. Jeong WK, Park JW, Choi HS, Chang HJ, Jeong SY: Transanal endoscopic microsurgery for rectal tumors: experience at Korea's National Cancer Center. Surg Endosc; 2009 Nov;23(11):2575-9
Genetic Alliance. consumer health - Rectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Transanal endoscopic microsurgery for rectal tumors: experience at Korea's National Cancer Center.
  • BACKGROUND: Transanal endoscopic microsurgery (TEM) is a minimally invasive alternative to transanal excision, enabling complete local excision of selected benign or malignant rectal tumors.
  • This study aimed to determine the surgical and oncologic results for rectal tumors excised by TEM.
  • METHODS: From November 2001 to October 2007, 45 patients underwent TEM for excision of adenoma (13 patients), carcinoid tumor (6 patients), and carcinoma (26 patients).
  • RESULTS: The median tumor distance from the anal verge was 7 cm (range, 3-15 cm), and the median tumor size was 17 mm (range, 2-60 mm).
  • No recurrence occurred for six patients with carcinoid tumors.
  • Histologic examination of the carcinomas showed pathologic tumor (pT) stage 0 (ypT0) in 2 patients, pT1 in 17 patients (including ypT1 in 1 patient), pT2 in 6 patients, and pT3 in 1 patient.
  • CONCLUSIONS: The TEM procedure is a safe and appropriate surgical treatment option for benign rectal tumors.
  • [MeSH-major] Anal Canal / surgery. Microsurgery / methods. Neoplasm Recurrence, Local / pathology. Proctoscopy / methods. Rectal Neoplasms / pathology. Rectal Neoplasms / surgery
  • [MeSH-minor] Adenocarcinoma / mortality. Adenocarcinoma / pathology. Adenocarcinoma / surgery. Adenoma / mortality. Adenoma / pathology. Adenoma / surgery. Adult. Aged. Cancer Care Facilities. Carcinoid Tumor / mortality. Carcinoid Tumor / pathology. Carcinoid Tumor / surgery. Cohort Studies. Disease-Free Survival. Female. Follow-Up Studies. Humans. Immunohistochemistry. Intestinal Mucosa / pathology. Intestinal Mucosa / surgery. Korea. Male. Middle Aged. Minimally Invasive Surgical Procedures / adverse effects. Minimally Invasive Surgical Procedures / methods. Neoplasm Staging. Patient Selection. Postoperative Complications / diagnosis. Postoperative Complications / surgery. Reoperation. Retrospective Studies. Risk Assessment. Survival Analysis. Treatment Outcome. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Surg. 2001 Sep;234(3):352-8; discussion 358-9 [11524588.001]
  • [Cites] Br J Surg. 1996 Feb;83(2):207-10 [8689164.001]
  • [Cites] Chirurg. 1984 Oct;55(10):677-80 [6510078.001]
  • [Cites] Anticancer Res. 2004 Mar-Apr;24(2C):1167-72 [15154642.001]
  • [Cites] Dis Colon Rectum. 1991 Oct;34(10):880-5 [1914721.001]
  • [Cites] J Clin Oncol. 1989 Aug;7(8):1003-8 [2754446.001]
  • [Cites] Arch Surg. 1998 Aug;133(8):894-9 [9711965.001]
  • [Cites] Surg Endosc. 2007 Jan;21(1):97-102 [17111281.001]
  • [Cites] Surg Endosc. 2003 Aug;17(8):1283-7 [12739119.001]
  • [Cites] Am J Surg. 2007 Nov;194(5):694-8 [17936438.001]
  • [Cites] Ann Surg Oncol. 2006 Apr;13(4):547-56 [16514476.001]
  • [Cites] Dis Colon Rectum. 2008 Jul;51(7):1026-30; discussion 1030-1 [18481147.001]
  • [Cites] Br J Surg. 2005 Dec;92(12):1546-52 [16252312.001]
  • [Cites] Dis Colon Rectum. 1996 Aug;39(8):886-92 [8756844.001]
  • [Cites] Am J Clin Oncol. 1994 Oct;17(5):411-6 [8092113.001]
  • [Cites] Colorectal Dis. 2004 Sep;6(5):350-5 [15335369.001]
  • [Cites] World J Surg. 1992 May-Jun;16(3):437-46 [1317077.001]
  • [Cites] Surg Endosc. 2002 Jun;16(6):989-95 [12163970.001]
  • [Cites] Ann Surg Oncol. 2003 Nov;10(9):1106-11 [14597451.001]
  • [Cites] Surg Endosc. 2007 Jun;21(6):970-4 [17285371.001]
  • [Cites] Br J Surg. 2007 May;94(5):627-33 [17335125.001]
  • [Cites] Dis Colon Rectum. 1996 Sep;39(9):969-76 [8797643.001]
  • [Cites] Dis Colon Rectum. 2000 Aug;43(8):1064-71; discussion 1071-4 [10950004.001]
  • [Cites] Arch Surg. 1998 Jun;133(6):595-8; discussion 598-9 [9637456.001]
  • [Cites] Colorectal Dis. 2006 Sep;8(7):581-5 [16919110.001]
  • [Cites] Dis Colon Rectum. 2005 Feb;48(2):270-84 [15711865.001]
  • (PMID = 19347399.001).
  • [ISSN] 1432-2218
  • [Journal-full-title] Surgical endoscopy
  • [ISO-abbreviation] Surg Endosc
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


31. Birkenkamp-Demtröder K, Wagner L, Brandt Sørensen F, Bording Astrup L, Gartner W, Scherübl H, Heine B, Christiansen P, Ørntoft TF: Secretagogin is a novel marker for neuroendocrine differentiation. Neuroendocrinology; 2005;82(2):121-38
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The aim of this study was to analyze the differential expression of secretagogin in normal mucosa, adenocarcinomas, and neuroendocrine tumors.
  • Tissues adjacent to benign hyperplasic polyps and adenomas showed a decreased number of secretagogin-expressing neuroendocrine cells.
  • Secretagogin co-localized with neuroendocrine markers (chromogranin A, neuron-specific enolase, synaptophysin) in neuroendocrine cells in crypts of normal mucosa, and in tumor cells of carcinoids.
  • Secretagogin was strongly expressed in the cytosol and the nucleus of 19 well-differentiated neuroendocrine carcinoids and carcinoid metastases, as well as in neuroendocrine tumors from the lung, pancreas and adrenal gland.
  • Secretagogin was detected in plasma from carcinoid patients with distant metastasis.
  • [MeSH-major] Calcium-Binding Proteins / metabolism. Neuroendocrine Tumors / metabolism
  • [MeSH-minor] Adenocarcinoma / metabolism. Adenocarcinoma / pathology. Adolescent. Adult. Aged. Aged, 80 and over. Biomarkers, Tumor. Blotting, Western. Carcinoid Tumor / metabolism. Carcinoid Tumor / pathology. Cell Differentiation / physiology. Chromogranin A. Chromogranins / metabolism. Female. Humans. Immunohistochemistry. Lung Neoplasms / secondary. Male. Microscopy, Fluorescence. Middle Aged. Neoplasm Metastasis. Oligonucleotide Array Sequence Analysis. Peptidylprolyl Isomerase / metabolism. Phosphopyruvate Hydratase / metabolism. Secretagogins. Synaptophysin / metabolism. Tacrolimus Binding Proteins / metabolism

  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16449819.001).
  • [ISSN] 0028-3835
  • [Journal-full-title] Neuroendocrinology
  • [ISO-abbreviation] Neuroendocrinology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Calcium-Binding Proteins; 0 / Chromogranin A; 0 / Chromogranins; 0 / SCGN protein, human; 0 / Secretagogins; 0 / Synaptophysin; EC 4.2.1.11 / Phosphopyruvate Hydratase; EC 5.2.1.- / Tacrolimus Binding Proteins; EC 5.2.1.8 / FKBP10 protein, human; EC 5.2.1.8 / Peptidylprolyl Isomerase
  •  go-up   go-down


32. Congregado M, Merchan RJ, Gallardo G, Ayarra J, Loscertales J: Video-assisted thoracic surgery (VATS) lobectomy: 13 years' experience. Surg Endosc; 2008 Aug;22(8):1852-7

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The clinical records of all patients were drawn from the hospital archive and data for the following variables were recorded for analysis: age, sex, clinical diagnosis, clinical status, date of surgery, type of surgery, inoperability, conversion to conventional surgery and reasons, duration of surgery and intraoperative complications, postoperative and long-term complications, postoperative stay, diagnosis, definitive status, and mortality.
  • RESULTS: A total of 237 major pulmonary resections were performed, on 203 males and 34 males, with a mean age of 61.43 years (non-small-cell bronchogenic carcinoma: 204, benign processes: 24, carcinoid tumors: 4, and lobectomy due to metastases: 5).
  • In our experience, VATS is currently to be considered ideally indicated for certain benign processes and for T1-T2 N0 M0 bronchogenic carcinomas.
  • [MeSH-minor] Adolescent. Adult. Aged. Carcinoid Tumor / surgery. Carcinoma, Bronchogenic / surgery. Child. Female. Follow-Up Studies. Humans. Length of Stay. Lung Diseases / surgery. Lung Neoplasms / pathology. Lung Neoplasms / surgery. Male. Middle Aged. Neoplasm Metastasis. Neoplasm Recurrence, Local. Neoplasm Staging. Pneumonectomy / adverse effects. Retrospective Studies. Survival Analysis. Time Factors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Semin Thorac Cardiovasc Surg. 1998 Oct;10(4):291-9 [9801250.001]
  • [Cites] Ann Thorac Surg. 2002 Mar;73(3):900-4 [11899198.001]
  • [Cites] Ann Thorac Surg. 2000 Jul;70(1):243-7 [10921716.001]
  • [Cites] Ann Ital Chir. 2000 Sep-Oct;71(5):539-43 [11217470.001]
  • [Cites] Eur J Cardiothorac Surg. 2001 Sep;20(3):455-63 [11509263.001]
  • [Cites] J Pediatr Surg. 2003 Jan;38(1):102-4 [12592629.001]
  • [Cites] Surg Today. 2003;33(1):7-12 [12560900.001]
  • [Cites] Ann Thorac Surg. 2006 Feb;81(2):421-5; discussion 425-6 [16427825.001]
  • [Cites] Ann Thorac Surg. 2001 Aug;72(2):362-5 [11515867.001]
  • [Cites] Eur J Cardiothorac Surg. 2004 Jul;26(1):158-64 [15200996.001]
  • [Cites] Eur J Cardiothorac Surg. 2006 Jun;29(6):997-1000 [16716918.001]
  • [Cites] Surg Endosc. 2003 Apr;17(4):632-5 [12582766.001]
  • [Cites] Chest. 1996 Jun;109(6):1636-42 [8769523.001]
  • [Cites] Ann Ital Chir. 2003 May-Jun;74(3):299-307 [14677287.001]
  • [Cites] Eur J Cardiothorac Surg. 2000 Jul;18(1):7-11 [10869933.001]
  • [Cites] World J Surg. 2000 Jan;24(1):27-30; discussion 30-1 [10594199.001]
  • [Cites] Eur J Cardiothorac Surg. 2006 May;29(5):806-9 [16581257.001]
  • [Cites] Semin Thorac Cardiovasc Surg. 1998 Oct;10(4):285-90 [9801249.001]
  • [Cites] Ann Thorac Surg. 2003 Oct;76(4):1009-14; discussion 1014-5 [14529976.001]
  • [Cites] Chest. 2004 Sep;126(3):725-32 [15364748.001]
  • [Cites] Surg Endosc. 2002 Jun;16(6):881-92 [12163949.001]
  • [Cites] Ann Thorac Surg. 2000 Nov;70(5):1644-6 [11093502.001]
  • [Cites] Eur J Cardiothorac Surg. 2001 Sep;20(3):437-42 [11509260.001]
  • [Cites] Thorac Cardiovasc Surg. 2006 Apr;54(3):202-7 [16639684.001]
  • [Cites] Eur J Cardiothorac Surg. 2003 Mar;23(3):397-402 [12614813.001]
  • (PMID = 18157567.001).
  • [ISSN] 1432-2218
  • [Journal-full-title] Surgical endoscopy
  • [ISO-abbreviation] Surg Endosc
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


33. Delle Fave G, Capurso G, Milione M, Panzuto F: Endocrine tumours of the stomach. Best Pract Res Clin Gastroenterol; 2005 Oct;19(5):659-73
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In fact, type I carcinoids can be considered to be benign lesions, with exceptional risk of metastases.
  • Several other candidates--including Bcl2, p53 and MMP9--have been linked with carcinoid initiation and progression.
  • [MeSH-major] Carcinoid Tumor / epidemiology. Carcinoid Tumor / pathology. Neoplasm Invasiveness / pathology. Stomach Neoplasms / epidemiology. Stomach Neoplasms / pathology
  • [MeSH-minor] Biopsy, Needle. Female. Gastrectomy / methods. Gastric Mucosa / pathology. Gastroscopy / methods. Humans. Immunohistochemistry. Incidence. Male. Neoplasm Staging. Prognosis. Risk Assessment. Survival Rate. Treatment Outcome. Zollinger-Ellison Syndrome / epidemiology. Zollinger-Ellison Syndrome / pathology. Zollinger-Ellison Syndrome / surgery

  • MedlinePlus Health Information. consumer health - Carcinoid Tumors.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16253892.001).
  • [ISSN] 1521-6918
  • [Journal-full-title] Best practice & research. Clinical gastroenterology
  • [ISO-abbreviation] Best Pract Res Clin Gastroenterol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 63
  •  go-up   go-down


34. Loizzi V, Cormio G, Resta L, Fattizzi N, Vicino M, Selvaggi L: Pseudo-Meigs syndrome and elevated CA125 associated with struma ovarii. Gynecol Oncol; 2005 Apr;97(1):282-4
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Struma ovarii is a rare form of ovarian neoplasm composed entirely and predominantly of thyroid tissue.
  • CASE: We report an unusual presentation of a postmenopausal woman with benign struma ovarii associated with pseudo-Meigs syndrome, hypertiroidism, and elevated CA125 serum level, and a large complex right pelvic mass thereby mimicking an ovarian cancer.
  • This rare condition should be considered in the differential diagnosis in patients with ascites and pleural effusions but with negative cytology.
  • [MeSH-major] CA-125 Antigen / blood. Carcinoid Tumor / blood. Meigs Syndrome / blood. Ovarian Neoplasms / blood. Struma Ovarii / blood
  • [MeSH-minor] Aged. Diagnosis, Differential. Female. Humans. Hyperthyroidism / blood

  • MedlinePlus Health Information. consumer health - Carcinoid Tumors.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15790478.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CA-125 Antigen
  •  go-up   go-down


35. Feo CF, Porcu A, Scanu AM, Ginesu GC, Fancellu A, Lorettu A, Dettori G: Primary appendiceal tumors: report on 10 cases. Int Surg; 2009 Jul-Sep;94(3):224-7
MedlinePlus Health Information. consumer health - Carcinoid Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary appendiceal tumors: report on 10 cases.
  • We report our experience on 10 patients with primary tumors of the appendix treated at our institution from 1998 to 2005.
  • Six tumors were malignant, and the remaining were benign.
  • Two of the four patients with benign tumors died from causes unrelated to the appendiceal neoplasm.
  • The 6 patients with malignant tumors and the other 2 with benign disease were alive and disease free after a mean follow-up of 43 months.
  • Despite the rarity of appendiceal primary tumors, surgeons should be aware of these neoplasms for making correct treatment decisions.
  • [MeSH-major] Adenocarcinoma / surgery. Appendiceal Neoplasms / surgery. Carcinoid Tumor / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20187516.001).
  • [ISSN] 0020-8868
  • [Journal-full-title] International surgery
  • [ISO-abbreviation] Int Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


36. Ganai S, Kanumuri P, Rao RS, Alexander AI: Local recurrence after transanal endoscopic microsurgery for rectal polyps and early cancers. Ann Surg Oncol; 2006 Apr;13(4):547-56
MedlinePlus Health Information. consumer health - Colonoscopy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: The study comprises 107 patients presenting for TEM with benign disease and 32 patients with cancer.
  • Pathologic classification of the lesions after TEM was benign adenoma in 45%, adenoma with high-grade dysplasia (HGD) in 17%, cancer in 33%, and other in 4%.
  • Recurrence of cancers correlated with the depth of tumor invasion (P<.05).
  • Five-year neoplastic recurrence probabilities were 11% for benign adenomas, 35% for adenomas with HGD, and 20% for cancers (P=.31); invasive recurrence probabilities were 0% for benign adenomas, 15% for adenomas with HGD, and 13% for cancers (P<.05).
  • CONCLUSIONS: Close endoscopic follow-up is warranted after TEM for both benign and malignant disease, with special attention to lesions with HGD.
  • [MeSH-major] Adenocarcinoma / pathology. Adenocarcinoma / surgery. Adenoma / pathology. Adenoma / surgery. Carcinoid Tumor / pathology. Carcinoid Tumor / surgery. Colonoscopy. Intestinal Polyps / pathology. Intestinal Polyps / surgery. Microsurgery. Neoplasm Recurrence, Local. Rectal Neoplasms / pathology. Rectal Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Neoplasm Invasiveness. Retrospective Studies. Survival Analysis

  • MedlinePlus Health Information. consumer health - Carcinoid Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16514476.001).
  • [ISSN] 1068-9265
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


37. Sigurdardottir JM, Isaksson HJ, Johannsson KB, Jonsson S, Gudbjartsson T: [Histology does not accurately predict the clinical behaviour of bronchopulmonary carcinoids - results from an Icelandic population-based study]. Laeknabladid; 2008 Feb;94(2):125-30
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND AND AIMS: Bronchopulmonary carcinoids (BPC) are rare tumors of neuroendocrine origin.
  • These tumors are histologically classified into two distinctive forms, typical and the more malignant atypical BPC.
  • Average tumor-diameter was 2.5 cm (range 0.4-5.5), with typical histology in 54 (84%) and atypical in 10 patients (16%).
  • CONCLUSION: BPCs usually behave as benign neoplasms, with excellent long-term survival after surgical removal.
  • Therefore, histology (typical vs. atypical) can not be used with certainty to predict the clinical behaviour of these tumors.
  • [MeSH-major] Bronchial Neoplasms / pathology. Carcinoid Tumor / pathology. Lung Neoplasms / pathology
  • [MeSH-minor] Female. Humans. Iceland / epidemiology. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Staging. Pneumonectomy. Population Surveillance. Retrospective Studies. Time Factors. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Carcinoid Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18310777.001).
  • [ISSN] 0023-7213
  • [Journal-full-title] Læknablađiđ
  • [ISO-abbreviation] Laeknabladid
  • [Language] ice
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Iceland
  •  go-up   go-down


38. Radotra B, Awasthi A, Joshi K, Das A: Histopatholgical spectrum of thymic neoplasms: twelve-year experience at a referral hospital in north India. Indian J Pathol Microbiol; 2006 Jan;49(1):1-6
MedlinePlus Health Information. consumer health - Thymus Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A total of 96 thymectomy specimens were received during the study period (1992-2004), which consisted of 54 neoplasms and 42 benign lesions.
  • Among the neoplasms there were 48 thymic epithelial tumors, 3 thymolipomas and 3 thymic carcinoids.
  • [MeSH-minor] Adolescent. Adult. Aged. Carcinoid Tumor / pathology. Carcinoma / pathology. Child. Child, Preschool. Female. Humans. India. Lipoma / pathology. Male. Middle Aged. Myasthenia Gravis. Neoplasm Staging. Red-Cell Aplasia, Pure. Thymectomy. Thymoma / pathology. Thymus Gland / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16625962.001).
  • [ISSN] 0377-4929
  • [Journal-full-title] Indian journal of pathology & microbiology
  • [ISO-abbreviation] Indian J Pathol Microbiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  •  go-up   go-down


39. Yang WL, Zhang XC, Yan ZQ, Zhang HM, Zhao Z, Zhang JG, Wang YJ: [Clinical analysis of primary small intestinal neoplasms in 305 cases]. Zhonghua Zhong Liu Za Zhi; 2007 Oct;29(10):781-3
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To summarive the experience in diagnosis and treatment of primary small intestinal neoplasm.
  • METHODS: The data of 305 patients with pathologically confirmed primary small intestinal tumor collected from 6 hospitals around the Songhua River during the past 33 years were analyzed retrospectively.
  • RESULTS: There were 42 benign and 263 malignant tumors in this series with a ratio of 1: 6.26.
  • The 263 malignant tumors in this series consisted of 135 adenocarcinomas, 57 malignant stromal tumors, 37 malignant lymphomas, 20 carcinoids, and etc.
  • Chronic occult bleeding, gradual of body weight loss and mild abdominal pain (three obscurities) were the common clinical features and alerting massage of intestinal tumor.
  • Correct preoperative diagnostic rate was only 57.0% (174/305) due to difficulty in early diagnosis, which was 67.2% (92/137) in the duodenal tumors, and 51.9% (82/168) in the jejunoileal tumors.
  • All of the 42 benign tumors were resected completely.
  • For the 263 patients with malignant tumors, radical dissection was performed in 153, palliative resection in 34, and gut by-pass or biopsy in 76.
  • The median survival of the patients who underwent radical resection of their malignant tumors was 92 months, which was significantly higher than that of the other groups.
  • CONCLUSION: Early diagnosis of primary small intestinal tumors is difficult and with a preoperative misdiagnosis rate of 43.0%.
  • Total intestinal barium swallowing, endoscopy and superior mesenteric arteriography are three critical examinations for diagnosis and location.
  • The primary small intestinal tumor should be resected as early as possible if no distant metastasis is detected.
  • [MeSH-minor] Adenoma / diagnosis. Adenoma / pathology. Adenoma / surgery. Adult. Aged. Aged, 80 and over. Carcinoid Tumor / diagnosis. Carcinoid Tumor / secondary. Carcinoid Tumor / surgery. Female. Gastrointestinal Stromal Tumors / diagnosis. Gastrointestinal Stromal Tumors / secondary. Gastrointestinal Stromal Tumors / surgery. Humans. Ileal Neoplasms / diagnosis. Ileal Neoplasms / pathology. Ileal Neoplasms / surgery. Jejunal Neoplasms / diagnosis. Jejunal Neoplasms / pathology. Jejunal Neoplasms / surgery. Liver Neoplasms / secondary. Liver Neoplasms / surgery. Lymphatic Metastasis. Lymphoma / diagnosis. Lymphoma / pathology. Lymphoma / surgery. Male. Middle Aged. Young Adult

  • MedlinePlus Health Information. consumer health - Intestinal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18396694.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


40. Portela-Gomes GM, Grimelius L, Stridsberg M: Immunohistochemical and biochemical studies with region-specific antibodies to chromogranins A and B and secretogranins II and III in neuroendocrine tumors. Cell Mol Neurobiol; 2010 Nov;30(8):1147-53
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunohistochemical and biochemical studies with region-specific antibodies to chromogranins A and B and secretogranins II and III in neuroendocrine tumors.
  • This short review deals with our investigations in neuroendocrine tumors (NETs) with antibodies against defined epitopes of chromogranins (Cgs) A and B and secretogranins (Sgs) II and III.
  • In most NETs one or more epitopes of the granins were lacking, but variations in the expression pattern occurred both in benign and malignant NETs.
  • A few epitopes displayed patterns that may be valuable in differentiating between benign and malignant NET types, e.g., well-differentiated NET types expressed more CgA epitopes than the poorly differentiated ones and C-terminal secretoneurin visualized a cell type related to malignancy in pheochromocytomas.
  • In patients suffering from carcinoid tumors or endocrine pancreatic tumors the highest concentrations were found with epitopes from the mid-portion of CgA.
  • Measurements of SgII showed that patients with endocrine pancreatic tumors had higher concentrations than patients with carcinoid tumors or pheochromocytomas.
  • [MeSH-major] Antibodies, Neoplasm / immunology. Chromogranins / immunology. Neuroendocrine Tumors / immunology

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Pathol. 2000 Oct;157(4):1299-309 [11021834.001]
  • [Cites] Regul Pept. 2007 Mar 1;139(1-3):80-3 [17116339.001]
  • [Cites] Cancer. 1991 Feb 1;67(3):663-72 [1702355.001]
  • [Cites] FEBS Lett. 1988 Jul 4;234(1):160-4 [3134253.001]
  • [Cites] Adv Exp Med Biol. 2000;482:193-203 [11192580.001]
  • [Cites] Regul Pept. 2004 Mar 15;117(3):219-27 [14749043.001]
  • [Cites] J Anat. 2008 Mar;212(3):229-34 [18221483.001]
  • [Cites] Endocr Pathol. 2003 Spring;14(1):3-23 [12746559.001]
  • [Cites] J Neurosci. 1990 Sep;10(9):3135-47 [2204688.001]
  • [Cites] Prog Neurobiol. 1995 May;46(1):49-70 [7568909.001]
  • [Cites] Regul Pept. 2005 Feb 15;125(1-3):193-9 [15582732.001]
  • [Cites] Cell Mol Life Sci. 2007 Nov;64(22):2863-86 [17717629.001]
  • [Cites] Adv Pharmacol. 1998;42:257-9 [9327893.001]
  • [Cites] Endocr Pathol. 2003 Spring;14 (1):37-48 [12746561.001]
  • [Cites] Adv Exp Med Biol. 2000;482:319-27 [11192592.001]
  • [Cites] Regul Pept. 2010 Nov 30;165(1):12-20 [20211659.001]
  • [Cites] Diabetes. 1986 Mar;35(3):300-5 [3512340.001]
  • [Cites] Virchows Arch. 2006 Apr;448(4):399-406 [16408221.001]
  • [Cites] J Biol Chem. 1996 Nov 8;271(45):28533-40 [8910482.001]
  • [Cites] Am J Surg Pathol. 2001 Oct;25(10):1261-7 [11688460.001]
  • [Cites] FEBS Lett. 1982 Oct 18;147(2):261-6 [6816630.001]
  • [Cites] Virchows Arch. 2005 Jun;446(6):604-12 [15906087.001]
  • [Cites] J Biol Chem. 1983 Sep 25;258(18):11326-34 [6577005.001]
  • [Cites] J Biol Chem. 1997 Apr 25;272(17):11657-62 [9111083.001]
  • [Cites] Proc Natl Acad Sci U S A. 1991 Feb 15;88(4):1426-30 [1996343.001]
  • [Cites] APMIS. 2004 Oct;112(10):663-73 [15601318.001]
  • [Cites] Am J Surg Pathol. 1988 Nov;12(11):877-84 [2847571.001]
  • [Cites] J Endocrinol. 1995 Jan;144(1):49-59 [7891024.001]
  • [Cites] Ann N Y Acad Sci. 1987;493:120-34 [3296906.001]
  • [Cites] N Engl J Med. 1986 May 1;314(18):1145-51 [3007986.001]
  • [Cites] Regul Pept. 2008 Jun 5;148(1-3):95-8 [18448176.001]
  • [Cites] Biochem J. 1991 Jun 1;276 ( Pt 2):471-9 [1710890.001]
  • [Cites] Mol Cell Endocrinol. 1981 Nov;24(2):181-93 [7297761.001]
  • [Cites] Int J Cancer. 2006 Apr 15;118(8):2003-12 [16287097.001]
  • [Cites] Biol Rev Camb Philos Soc. 2004 Nov;79(4):769-94 [15682870.001]
  • [Cites] Acta Oncol. 2004;43(7):617-25 [15545182.001]
  • [Cites] J Histochem Cytochem. 2002 Aug;50(8):1023-30 [12133905.001]
  • [Cites] Mol Pharmacol. 1966 Jul;2(4):298-310 [5968070.001]
  • [Cites] Am J Surg Pathol. 2002 May;26(5):551-66 [11979086.001]
  • [Cites] J Histochem Cytochem. 2001 Apr;49(4):483-90 [11259451.001]
  • [Cites] Regul Pept. 2010 Nov 30;165(1):30-5 [20550951.001]
  • [Cites] Virchows Arch. 1995;426(4):361-7 [7599788.001]
  • [Cites] Biochem J. 1965 Dec;97(3):40C-41C [5881651.001]
  • [Cites] Regul Pept. 2003 Jun 15;114(1):29-35 [12763637.001]
  • [Cites] Proc Natl Acad Sci U S A. 1985 Aug;82(16):5300-4 [3875097.001]
  • [Cites] J Histochem Cytochem. 1997 Jun;45(6):815-22 [9199667.001]
  • [Cites] J Pathol. 1999 Feb;187(3):321-5 [10398086.001]
  • (PMID = 21046454.001).
  • [ISSN] 1573-6830
  • [Journal-full-title] Cellular and molecular neurobiology
  • [ISO-abbreviation] Cell. Mol. Neurobiol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Neoplasm; 0 / Chromogranins
  •  go-up   go-down


41. Righi L, Volante M, Tavaglione V, Billè A, Daniele L, Angusti T, Inzani F, Pelosi G, Rindi G, Papotti M: Somatostatin receptor tissue distribution in lung neuroendocrine tumours: a clinicopathologic and immunohistochemical study of 218 'clinically aggressive' cases. Ann Oncol; 2010 Mar;21(3):548-55
University of Turin Instituional Repository AperTO. Full Text from .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • SSTR type 2A was strikingly overexpressed in metastatic TCs as compared with ACs and clinically benign TCs.

  • MedlinePlus Health Information. consumer health - Carcinoid Tumors.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19759190.001).
  • [ISSN] 1569-8041
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Receptors, Somatostatin; 0 / somatostatin receptor 2; 0 / somatostatin receptor 3
  •  go-up   go-down


42. Saba L, Guerriero S, Sulcis R, Virgilio B, Melis G, Mallarini G: Mature and immature ovarian teratomas: CT, US and MR imaging characteristics. Eur J Radiol; 2009 Dec;72(3):454-63
MedlinePlus Health Information. consumer health - Ultrasound.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Ovarian teratomas (OTs) are the most common germ cell neoplasm.
  • They include mature cystic teratomas, monodermal teratomas (neural tumors, struma ovarii, carcinoid tumors) and immature teratomas.
  • Teratomas are the most common benign ovarian neoplasms in women less than 45 years old.
  • [MeSH-major] Magnetic Resonance Imaging / methods. Ovarian Neoplasms / diagnosis. Teratoma / diagnosis. Tomography, X-Ray Computed / methods. Ultrasonography / methods

  • MedlinePlus Health Information. consumer health - CT Scans.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18804932.001).
  • [ISSN] 1872-7727
  • [Journal-full-title] European journal of radiology
  • [ISO-abbreviation] Eur J Radiol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Ireland
  • [Number-of-references] 93
  •  go-up   go-down


43. Bhatia P, Srinivasan R, Rajwanshi A, Nijhawan R, Khandelwal N, Wig J, Vasishtha RK: 5-year review and reappraisal of ultrasound-guided percutaneous transabdominal fine needle aspiration of pancreatic lesions. Acta Cytol; 2008 Sep-Oct;52(5):523-9
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Seven cases (2.6%) yielded insufficient material for diagnosis; 260 cases were classified as benign (n=118) and malignant (n=142) lesions.
  • Of the 118 benign aspirates, the cytodiagnosis was acute/chronic inflammation in 24, tuberculosis in 1, benign cyst in 10 and a benign aspirate, not otherwise specified, in the remaining 83 cases.
  • Of the 142 malignant aspirates, the cytodiagnosis was adenocarcinoma in 126, neuroendocrine/carcinoid tumor in 7, papillary solid epithelial neoplasm in 2, mucinous cystadenocarcinoma in 2, acinar cell carcinoma in 1 and metastatic small cell carcinoma in lung in 4 cases.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Acta Cytol. 2008 Sep-Oct;52(5):521-2 [18833811.001]
  • (PMID = 18833812.001).
  • [ISSN] 0001-5547
  • [Journal-full-title] Acta cytologica
  • [ISO-abbreviation] Acta Cytol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


44. Faith A, Peek E, McDonald J, Urry Z, Richards DF, Tan C, Santis G, Hawrylowicz C: Plasmacytoid dendritic cells from human lung cancer draining lymph nodes induce Tc1 responses. Am J Respir Cell Mol Biol; 2007 Mar;36(3):360-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Dendritic cells (DC) resident in draining lymph nodes (LN) of patients with lung cancer are proposed to have a critical role in stimulating anti-tumor immunity.
  • The present study, therefore, investigated the capacity of plasmacytoid-DC from human lung cancer draining LN to respond to CpG for activation of T cell responses relevant to anti-tumor immunity.
  • There was no significant difference between the responses of plasmacytoid-DC from patients with lung cancer and patients with benign carcinoid tumors with no pathologic LN involvement.

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17023687.001).
  • [ISSN] 1044-1549
  • [Journal-full-title] American journal of respiratory cell and molecular biology
  • [ISO-abbreviation] Am. J. Respir. Cell Mol. Biol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / HLA-DR Antigens; 0 / Interferon Type I; 0 / Oligonucleotides; 0 / Toll-Like Receptor 9; 147205-72-9 / CD40 Ligand; 82115-62-6 / Interferon-gamma
  •  go-up   go-down


45. Ruiz-Tovar J, Priego P, Martínez-Molina E, Morales V, Sanjuanbenito A, Lobo E: Pancreatic neuroendocrine tumours. Clin Transl Oncol; 2008 Aug;10(8):493-7
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • There were 28 insulinomas, eight glucagonomas, three gastrinomas, one VIPoma and one carcinoid.
  • 39 cases showed benign histologic features and ten malignant ones.
  • Actuarial mean survival was 163 months and was longer in insulinomas, in those tumours completely resected and in tumours with benign histological features.
  • [MeSH-major] Neuroendocrine Tumors / mortality. Pancreatic Neoplasms / mortality
  • [MeSH-minor] Adolescent. Adult. Aged. Female. Gastrinoma / pathology. Gastrinoma / surgery. Glucagonoma / pathology. Glucagonoma / surgery. Humans. Insulinoma / pathology. Insulinoma / surgery. Male. Middle Aged. Neoplasm Staging. Pancreatic Fistula / pathology. Pancreatic Fistula / surgery. Pancreaticoduodenectomy. Prognosis. Retrospective Studies. Survival Rate. Treatment Outcome. Vipoma / pathology. Vipoma / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2002 Jun 1;20(11):2633-42 [12039924.001]
  • [Cites] Surgery. 2003 Dec;134(6):1057-63; discussion 1063-5 [14668741.001]
  • [Cites] Ann Surg. 2007 Feb;245(2):273-81 [17245182.001]
  • [Cites] Am J Surg. 2007 May;193(5):610-3; discussion 613 [17434366.001]
  • [Cites] Arch Surg. 2006 Oct;141(10):1000-4; discussion 1005 [17043278.001]
  • [Cites] Rev Esp Enferm Dig. 2007 Apr;99(4):218-22 [17590104.001]
  • [Cites] Am J Surg. 1994 Dec;168(6):627-9; discussion 629-30 [7978008.001]
  • [Cites] Curr Probl Surg. 1994 Feb;31(2):77-156 [7904550.001]
  • [Cites] Surgery. 2001 Dec;130(6):1078-85 [11742342.001]
  • (PMID = 18667380.001).
  • [ISSN] 1699-048X
  • [Journal-full-title] Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
  • [ISO-abbreviation] Clin Transl Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


46. Hofer MD, Tapia C, Browne TJ, Mirlacher M, Sauter G, Rubin MA: Comprehensive analysis of the expression of the metastasis-associated gene 1 in human neoplastic tissue. Arch Pathol Lab Med; 2006 Jul;130(7):989-96
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To analyze MTA1 expression levels in a wide variety of human tumors.
  • RESULTS: Both analyses show that MTA1 is ubiquitously expressed in benign and malignant tumors.
  • The highest levels of MTA1 expression were observed in diffuse B-cell lymphoma (mean staining intensity, 3.9/4), basal cell carcinomas (3.7/4), and consistently in tumors of neuroendocrine descent such as paraganglioma (3.7/4) and carcinoid tumor (3.1/4).
  • CONCLUSIONS: This study characterizes MTA1 expression for the first time across a broad spectrum of primary tumors, demonstrating expression in both benign and malignant neoplasms in addition to showing an association with neuroendocrine differentiation.
  • [MeSH-minor] Biomarkers, Tumor / metabolism. Databases, Genetic. Humans. Immunohistochemistry. Neoplasm Invasiveness. Oligonucleotide Array Sequence Analysis. Software. Tissue Array Analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16831056.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Repressor Proteins; EC 3.5.1.- / Mta1 protein, human; EC 3.5.1.98 / Histone Deacetylases
  •  go-up   go-down


47. Gaissert HA, Grillo HC, Shadmehr MB, Wright CD, Gokhale M, Wain JC, Mathisen DJ: Uncommon primary tracheal tumors. Ann Thorac Surg; 2006 Jul;82(1):268-72; discussion 272-3
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Uncommon primary tracheal tumors.
  • BACKGROUND: Primary tracheal tumors other than adenoid cystic or squamous cell carcinoma are uncommon and have a heterogeneous histologic appearance.
  • METHODS: A retrospective analysis was performed of uncommon tracheal tumors among 360 primary tracheal tumors seen over 40 years, excluding adenoid cystic and squamous cell carcinoma.
  • RESULTS: Of 90 patients, 34 (38%) had benign tumors and 56 malignant: 11 carcinoid tumors, 14 mucoepidermoid carcinomas, 13 sarcomas, 15 nonsquamous bronchogenic carcinomas, 2 lymphomas, and 1 melanoma.
  • Dyspnea was the most common symptom in benign tumors and hemoptysis in malignant tumors.
  • After resection, survival at 10 years was 94% for benign and 83% for carcinoid tumors, and at 5 years survival was 60% for bronchogenic carcinoma, 100% for mucoepidermoid tumors, and 78% for sarcomas.
  • CONCLUSIONS: Surgical resection of uncommon primary tracheal tumors alleviates airway obstruction, is curative in patients with benign or slow-growing malignant lesions, and prolongs survival in highly malignant lesions.
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Bronchi / surgery. Bronchoscopy. Child. Child, Preschool. Combined Modality Therapy. Female. Follow-Up Studies. Hospital Mortality. Humans. Laryngeal Neoplasms / epidemiology. Laryngeal Neoplasms / pathology. Laryngeal Neoplasms / surgery. Laryngectomy. Life Tables. Male. Middle Aged. Neoplasm Metastasis. Neoplasm Recurrence, Local / epidemiology. Postoperative Complications / epidemiology. Radiotherapy, Adjuvant. Reoperation. Retrospective Studies. Survival Analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16798228.001).
  • [ISSN] 1552-6259
  • [Journal-full-title] The Annals of thoracic surgery
  • [ISO-abbreviation] Ann. Thorac. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


48. Zhou X, Shang JQ, Zhou JN: [Transsacral local wide resection for mid-lower rectal tumors]. Zhonghua Wei Chang Wai Ke Za Zhi; 2009 Jan;12(1):44-7

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Transsacral local wide resection for mid-lower rectal tumors].
  • OBJECTIVE: To evaluate the efficacy of transsacral local wide resection for mid-lower rectal tumors.
  • METHODS: Clinical data of 133 patients undergone transsacral local wide resection for mid-lower rectal tumors between September 1994 and September 2005 were analyzed retrospectively.
  • Postoperative diagnosis was adenoma in 28 patients, hyperplastic polyp in 3 patients, carcinoid in 8 patients, gastrointestinal stromal tumor in 1 patient,adenoma with intra-mucosal carcinogenesis in 29 patients and adenocarcinoma invading into submucosa in 64 patients.
  • CONCLUSION: Transsacral local wide resection is simple and safe for mid-lower rectal tumors, which is an appropriate procedure for mid-lower rectal benign tumor and can serve as a sphincter-saving operation for selected T(1) lower rectal carcinoma.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Neoplasm Staging. Retrospective Studies. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19145503.001).
  • [ISSN] 1671-0274
  • [Journal-full-title] Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  • [ISO-abbreviation] Zhonghua Wei Chang Wai Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


49. Fang HQ, Yang J, Zhang FF, Cui Y, Han AJ: Clinicopathological features of gastric glomus tumor. World J Gastroenterol; 2010 Sep 28;16(36):4616-20
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinicopathological features of gastric glomus tumor.
  • AIM: To study the clinicopathological features of gastric glomus tumor and review the related Chinese literature published in 1990-2010.
  • METHODS: A case of gastric glomus tumor was reported.
  • Clinicopathological findings in 56 cases of gastric glomus tumor were analyzed.
  • RESULTS: Gastric glomus tumor was far more common in women than in men with a female to male ratio of 1.6:1.
  • The tumor was located in antrum of the stomach.
  • The greatest diameter of the tumor was 0.8-11 cm.
  • Histologically, the tumor was comprised of nests of glomus cells surrounding the capillaries.
  • Vimentin, smooth muscle actin and actin were expressed in the tumor.
  • CONCLUSION: Gastric glomus tumor is a rare benign mesenchymal neoplasm.
  • Its diagnosis depends on pathologic examination.
  • Differential diagnosis includes gastrointestinal stromal tumor, paraganglioma and carcinoid tumor.
  • [MeSH-major] Glomus Tumor. Stomach Neoplasms

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Surg Pathol. 2002 Mar;26(3):301-11 [11859201.001]
  • [Cites] Abdom Imaging. 2010 Aug;35(4):390-2 [19554363.001]
  • [Cites] Ann Diagn Pathol. 2004 Feb;8(1):32-5 [15129908.001]
  • [Cites] Am J Clin Pathol. 1981 Mar;75(3):415-9 [6259931.001]
  • [Cites] J Postgrad Med. 1982 Apr;28(2):118-120B [6290654.001]
  • [Cites] Vopr Onkol. 1986;32(5):100-2 [3012879.001]
  • [Cites] Vopr Onkol. 1986;32(8):106-7 [3020794.001]
  • [Cites] Am J Surg Pathol. 1992 Mar;16(3):291-9 [1317998.001]
  • [Cites] Cancer. 1951 Jul;4(4):726-36 [14859193.001]
  • [Cites] J Clin Gastroenterol. 2006 Sep;40(8):717-20 [16940885.001]
  • [Cites] J Clin Ultrasound. 2007 Mar-Apr;35(3):164-8 [17295269.001]
  • [Cites] Med Sci Monit. 2008 Jan;14(1):CS5-8 [18160947.001]
  • [Cites] Indian J Pathol Microbiol. 2009 Jan-Mar;52(1):77-9 [19136789.001]
  • [Cites] J BUON. 2008 Oct-Dec;13(4):581-4 [19145686.001]
  • [Cites] Clin Exp Dermatol. 2009 Dec;34(8):e719-21 [19758389.001]
  • [Cites] Endoscopy. 2010;42 Suppl 2:E58-9 [20157891.001]
  • [Cites] Virchows Arch. 2010 Feb;456(2):111-27 [20165865.001]
  • [Cites] World J Surg Oncol. 2010;8:19 [20307271.001]
  • [Cites] Acta Cytol. 2002 May-Jun;46(3):560-6 [12040654.001]
  • (PMID = 20857536.001).
  • [ISSN] 2219-2840
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  • [Other-IDs] NLM/ PMC2945497
  •  go-up   go-down


50. Zhao ZL, Huang QY, Xu S, Zhang L, Zhao HR: [Expression of promyelocytic leukaemia protein in lung carcinomas and clinical significance thereof]. Zhonghua Yi Xue Za Zhi; 2006 Dec 19;86(47):3362-6
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: A tumor tissue microarray with lung samples from 148 patients with lung carcinoma and 5 patients with pulmonary benign tumor, and 7 patients with other benign diseases resected during operation.
  • The cases with at least triplicate 0.6-mm cores per tumor or tissue were analyzed.
  • The remaining 144 lung carcinoma cases included 45 cases with squamous cell carcinoma, 62 with adenocarcinoma, 23 with small cell lung carcinoma (SCLC), 7 with large cell carcinoma, 5 with pleomorphic carcinoma, 1 with carcinoid, and 1 with adenosquamous carcinoma.
  • Among the 5 cases with benign lung tumors, two cases with pulmonary leiomyomas had strong expression of PML.
  • CONCLUSION: As an important suppressor of tumor, PML may be a useful indicator to predict postoperative prognosis in patients with SCLC.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / metabolism. Carcinoma, Small Cell / metabolism. Lung Neoplasms / metabolism. Neoplasm Proteins / biosynthesis. Nuclear Proteins / biosynthesis. Transcription Factors / biosynthesis. Tumor Suppressor Proteins / biosynthesis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17313836.001).
  • [ISSN] 0376-2491
  • [Journal-full-title] Zhonghua yi xue za zhi
  • [ISO-abbreviation] Zhonghua Yi Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Neoplasm Proteins; 0 / Nuclear Proteins; 0 / Transcription Factors; 0 / Tumor Suppressor Proteins; 143220-95-5 / PML protein, human
  •  go-up   go-down


51. Saliba I, Evrard AS: Middle ear glandular neoplasms: adenoma, carcinoma or adenoma with neuroendocrine differentiation: a case series. Cases J; 2009;2:6508

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • It is currently thought that these tumors are indistinguishable each from another.
  • Herein, we present a new case of a middle ear glandular neoplasm.
  • Our objective is to review all cases described in the literature in order to identify the clinical features, the gross pathology, the histopathology, the immunohistochemistry, to discuss the differential diagnosis, the treatment, the rate of recurrence, the follow-up, the incidence of metastasis, the prognosis and to present a new classification of middle ear glandular neoplasm.
  • We uncovered 75 patients with a carcinoid tumor and 19 patients with a middle ear adenoma diagnosis; the most common presenting symptom was a conductive hearing loss.
  • The tumor's cells are immunohistochemically positive for a variety of keratin antibodies and most of them are also positive for neuroendocrine markers.
  • CONCLUSIONS: Our study and the review of the literature showed adenomas and carcinoid tumors of the middle ear to be essentially indistinguishable benign tumors with metastatic potential.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Otolaryngol Allied Sci. 1976;1(1):17-26 [1031337.001]
  • [Cites] Auris Nasus Larynx. 2009 Feb;36(1):75-8 [18328653.001]
  • [Cites] Ann Otol Rhinol Laryngol. 1989 Sep;98(9):749-52 [2782809.001]
  • [Cites] Acta Pathol Jpn. 1988 Nov;38(11):1453-60 [3223280.001]
  • [Cites] J Laryngol Otol. 1987 May;101(5):480-6 [3585164.001]
  • [Cites] Am J Clin Pathol. 1980 Jun;73(6):816-23 [6156597.001]
  • [Cites] Ann Pathol. 1993;13(3):170-5 [7691060.001]
  • [Cites] Histopathology. 1997 Apr;30(4):359-64 [9147085.001]
  • [Cites] Eur Arch Otorhinolaryngol. 1998;255(2):57-61 [9550256.001]
  • [Cites] Histopathology. 1998 Mar;32(3):279-80 [9568517.001]
  • [Cites] Head Neck. 1999 Jan;21(1):72-7 [9890354.001]
  • [Cites] Pathology. 1999 Aug;31(3):284-7 [10503278.001]
  • [Cites] Neuroradiology. 2001 Jan;43(1):58-61 [11214650.001]
  • [Cites] Mod Pathol. 2002 May;15(5):543-55 [12011260.001]
  • [Cites] Acta Otolaryngol. 2003 Aug;123(6):678-82 [12953765.001]
  • [Cites] Acta Otolaryngol. 2004 Aug;124(6):754-7 [15515504.001]
  • [Cites] Head Neck. 2005 Jul;27(7):644-7 [15825200.001]
  • [Cites] Laryngoscope. 2005 Sep;115(9):1660-6 [16148713.001]
  • [Cites] Ear Nose Throat J. 2005 Sep;84(9):560-1 [16261754.001]
  • [Cites] Oral Oncol. 2006 Sep;42(8):770-88 [16815077.001]
  • [Cites] Clin Nucl Med. 2007 Jun;32(6):466-7 [17515757.001]
  • [Cites] Ann Otol Rhinol Laryngol. 1990 Jul;99(7 Pt 1):547-52 [2164339.001]
  • (PMID = 20111612.001).
  • [ISSN] 1757-1626
  • [Journal-full-title] Cases journal
  • [ISO-abbreviation] Cases J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2812983
  •  go-up   go-down


52. Buck AK, Hetzel M, Schirrmeister H, Halter G, Möller P, Kratochwil C, Wahl A, Glatting G, Mottaghy FM, Mattfeldt T, Neumaier B, Reske SN: Clinical relevance of imaging proliferative activity in lung nodules. Eur J Nucl Med Mol Imaging; 2005 May;32(5):525-33

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In this prospective study, we examined the accuracy of FLT for differentiation of benign from malignant lung lesions and for tumour staging.
  • RESULTS: Histopathology revealed malignant lung tumours in 32 patients (20 non-small cell lung cancer, 1 small cell lung cancer, 1 pulmonary carcinoid, 1 non-Hodgkin's lymphoma, nine metastases from extrapulmonary tumours) and benign lesions in 15 patients.
  • FLT-PET was false negative in two patients with non-small cell lung cancer, in the patient with a pulmonary carcinoid and in three patients with lung metastases.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Lung Neoplasms / classification. Lung Neoplasms / diagnostic imaging. Lung Neoplasms / pathology. Male. Middle Aged. Neoplasm Invasiveness. Neoplasm Staging. Radionuclide Imaging. Radiopharmaceuticals. Reproducibility of Results. Sensitivity and Specificity. Severity of Illness Index

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur J Nucl Med Mol Imaging. 2002 Nov;29(11):1462-9 [12397465.001]
  • [Cites] J Nucl Med. 2003 Dec;44(12 ):1927-32 [14660718.001]
  • [Cites] Cancer Res. 2002 Jun 15;62(12 ):3331-4 [12067968.001]
  • [Cites] J Nucl Med. 2001 May;42(5):721-5 [11337566.001]
  • [Cites] J Nucl Med. 2004 Oct;45(10 ):1754-8 [15471845.001]
  • [Cites] Antimicrob Agents Chemother. 1992 Apr;36(4):808-18 [1503443.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2002 Sep;29(9):1174-81 [12192562.001]
  • [Cites] Eur J Nucl Med. 1994 Sep;21(9):930-6 [7995286.001]
  • [Cites] J Clin Oncol. 2001 Jan 1;19(1):111-8 [11134203.001]
  • [Cites] J Nucl Med. 2004 Apr;45(4):695-700 [15073267.001]
  • [Cites] J Nucl Med. 2003 Sep;44(9):1426-31 [12960187.001]
  • [Cites] Clin Cancer Res. 2004 Mar 1;10 (5):1685-90 [15014020.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2002 Feb;29(2):165-9 [11926377.001]
  • [Cites] J Nucl Med. 2001 Nov;42(11):1596-604 [11696627.001]
  • [Cites] J Nucl Med. 1994 Jan;35(1):104-12 [8271030.001]
  • [Cites] Nucl Med Biol. 1996 Jan;23 (1):17-22 [9004909.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2003 Jul;30(7):988-94 [12739071.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2004 Jun;31(6):928 [15034675.001]
  • [Cites] JAMA. 2001 Feb 21;285(7):914-24 [11180735.001]
  • [Cites] Cancer Res. 2003 Jul 1;63(13):3791-8 [12839975.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2003 Oct;30(10 ):1407-12 [12898201.001]
  • [Cites] Radiographics. 1999 Jan-Feb;19(1):61-77; quiz 150-1 [9925392.001]
  • [Cites] J Nucl Med. 2002 Sep;43(9):1210-7 [12215561.001]
  • [Cites] J Nucl Med. 2004 Mar;45(3):519-25 [15001697.001]
  • [Cites] Cancer Res. 1999 Feb 1;59(3):615-21 [9973209.001]
  • [Cites] J Nucl Med. 2002 Dec;43(12):1688-98 [12468521.001]
  • [Cites] Pneumologie. 2001 Aug;55(8):367-77 [11505288.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2004 Feb;31(2):169-78 [15129698.001]
  • [Cites] J Clin Oncol. 1999 Oct;17 (10 ):3201-6 [10506619.001]
  • [Cites] J Nucl Med. 1984 Jul;25(7):759-64 [6610731.001]
  • [Cites] Cancer Res. 2001 Mar 15;61(6):2500-4 [11289121.001]
  • [Cites] Clin Cancer Res. 2002 Nov;8(11):3315-23 [12429617.001]
  • [Cites] J Nucl Med. 2003 Sep;44(9):1432-4 [12960188.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2004 May;31(5):720-4 [14991243.001]
  • [Cites] Nat Med. 1998 Nov;4(11):1334-6 [9809561.001]
  • (PMID = 15599526.001).
  • [ISSN] 1619-7070
  • [Journal-full-title] European journal of nuclear medicine and molecular imaging
  • [ISO-abbreviation] Eur. J. Nucl. Med. Mol. Imaging
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Dideoxynucleosides; 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18; PG53R0DWDQ / alovudine
  •  go-up   go-down


53. Krstić M, Sumarac M, Diklić A, Tatić S, Pavlović A, Tomić D, Micić D, Kendereski A, Milinić N, Petakov M: [Endoscopic ultrasonography (EUS) in preoperative localization of neuroendocrine tumors (NET) of the pancreas]. Acta Chir Iugosl; 2005;52(1):97-100
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Endoscopic ultrasonography (EUS) in preoperative localization of neuroendocrine tumors (NET) of the pancreas].
  • We studied the location, the size and echo-pattern of the neoplasm.
  • Six tumours were benign (75%), and two were malign (25%).
  • We localized 6 insulinomas and single pancreatic carcinoid tumour.
  • [MeSH-major] Endosonography. Neuroendocrine Tumors / ultrasonography. Pancreatic Neoplasms / ultrasonography

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16119321.001).
  • [ISSN] 0354-950X
  • [Journal-full-title] Acta chirurgica Iugoslavica
  • [ISO-abbreviation] Acta Chir Iugosl
  • [Language] srp
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Serbia and Montenegro
  •  go-up   go-down


54. Yamauchi N, Watanabe A, Hishinuma M, Ohashi K, Midorikawa Y, Morishita Y, Niki T, Shibahara J, Mori M, Makuuchi M, Hippo Y, Kodama T, Iwanari H, Aburatani H, Fukayama M: The glypican 3 oncofetal protein is a promising diagnostic marker for hepatocellular carcinoma. Mod Pathol; 2005 Dec;18(12):1591-8
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Then, we evaluated the feasibility of GPC3-immunohistochemistry in the pathological diagnosis of benign and malignant hepatocellular lesions by applying these monoclonal antibodies to formalin-fixed and paraffin-embedded specimens.
  • GPC3 immunoreactivity was detected in only one of 23 metastatic lesions of colorectal carcinoma, and its expression was entirely absent in the liver cell adenoma (0/7), carcinoid tumor (0/1), and cholangiocellular carcinoma (0/16).
  • [MeSH-major] Antigens, Neoplasm / metabolism. Biomarkers, Tumor / metabolism. Carcinoma, Hepatocellular / diagnosis. Heparan Sulfate Proteoglycans / metabolism. Liver Neoplasms / diagnosis
  • [MeSH-minor] Antibodies, Monoclonal / biosynthesis. Antibodies, Monoclonal / immunology. Cell Line, Tumor. Glypicans. Hepatoblastoma / metabolism. Hepatoblastoma / pathology. Hepatocytes / metabolism. Hepatocytes / pathology. Humans. Liver / embryology. Liver / metabolism. Lung Neoplasms / metabolism. Lung Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15920546.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / Glypicans; 0 / Heparan Sulfate Proteoglycans
  •  go-up   go-down


55. Tsai BM, Finne CO, Nordenstam JF, Christoforidis D, Madoff RD, Mellgren A: Transanal endoscopic microsurgery resection of rectal tumors: outcomes and recommendations. Dis Colon Rectum; 2010 Jan;53(1):16-23
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Transanal endoscopic microsurgery resection of rectal tumors: outcomes and recommendations.
  • PURPOSE: Transanal endoscopic microsurgery provides a minimally invasive alternative to radical surgery for excision of benign and malignant rectal tumors.
  • We analyzed patient and operative factors, complications, and tumor recurrence.
  • RESULTS: Two hundred sixty-nine patients underwent transanal endoscopic microsurgery for benign (n = 158) and malignant (n = 111) tumors.
  • Local recurrence rates for 121 benign and 83 malignant tumors were 5% for adenomas, 9.8% for T1 adenocarcinoma, 23.5% for T2 adenocarcinoma, 100% for T3 adenocarcinoma, and 0% for carcinoid tumors.
  • CONCLUSIONS: Transanal endoscopic microsurgery is a safe and effective method for excision of benign and malignant rectal tumors.
  • Transanal endoscopic microsurgery can be offered for (1) curative resection of benign tumors, carcinoid tumors, and select T1 adenocarcinomas, (2) histopathologic staging in indeterminate cases, and (3) palliative resection in patients medically unfit or unwilling to undergo radical resection.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20010345.001).
  • [ISSN] 1530-0358
  • [Journal-full-title] Diseases of the colon and rectum
  • [ISO-abbreviation] Dis. Colon Rectum
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


56. Røkke O, Faerden AE, Øvrebø K: [Transanal endoscopic microsurgery for tumours in rectum]. Tidsskr Nor Laegeforen; 2007 Nov 15;127(22):2954-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Rectal tumors up to 25 cm from the anal verge may be resected by transanal endoscopic microsurgery (TEM).
  • TEM is suitable for resection of benign adenomas, but can also be used for selected malignant tumours.
  • Selected malignant tumours (like small carcinoid tumours and early stage [Tis, T1] adencarcinomas) with higer moderate differentiation may be resected by TEM with the same oncological result as open surgery.
  • TEM is especially suitable to resect benign adenomas, and may also have a place as primary treatment of selected malignant tumours in Norway.
  • [MeSH-minor] Humans. Neoplasm Recurrence, Local. Postoperative Complications / diagnosis. Proctoscopes

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18026244.001).
  • [ISSN] 0807-7096
  • [Journal-full-title] Tidsskrift for den Norske lægeforening : tidsskrift for praktisk medicin, ny række
  • [ISO-abbreviation] Tidsskr. Nor. Laegeforen.
  • [Language] nor
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Norway
  • [Number-of-references] 50
  •  go-up   go-down


57. Kim K, Kim HK, Park JS, Chang SW, Choi YS, Kim J, Shim YM: Video-assisted thoracic surgery lobectomy: single institutional experience with 704 cases. Ann Thorac Surg; 2010 Jun;89(6):S2118-22
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: Between 2003 and 2008, 704 patients underwent VATS lobectomy for the following indications: NSCLC (n = 548), carcinoid tumors (n = 7), pulmonary metastases (n = 22), and benign diseases (n = 127).
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Child. Feasibility Studies. Female. Humans. Male. Middle Aged. Neoplasm Recurrence, Local / epidemiology. Retrospective Studies. Survival Rate. Time Factors. Young Adult

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2010 The Society of Thoracic Surgeons. Published by Elsevier Inc. All rights reserved.
  • (PMID = 20493994.001).
  • [ISSN] 1552-6259
  • [Journal-full-title] The Annals of thoracic surgery
  • [ISO-abbreviation] Ann. Thorac. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


58. Fainstein Day P, Frohman L, Garcia Rivello H, Reubi JC, Sevlever G, Glerean M, Fernandez Gianotti T, Pietrani M, Rabadan A, Racioppi S, Bidlingmaier M: Ectopic growth hormone-releasing hormone secretion by a metastatic bronchial carcinoid tumor: a case with a non hypophysial intracranial tumor that shrank during long acting octreotide treatment. Pituitary; 2007;10(3):311-9
MedlinePlus Health Information. consumer health - Carcinoid Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ectopic growth hormone-releasing hormone secretion by a metastatic bronchial carcinoid tumor: a case with a non hypophysial intracranial tumor that shrank during long acting octreotide treatment.
  • Although clinical improvement is common after treatment with somatostatin (SMS) analogs, the biochemical response and tumor size of the growth hormone-releasing hormone (GHRH)-producing tumor and its metastases are less predictable.
  • He had undergone lung surgery in 1987 for a "benign" carcinoid tumor.
  • Methods Measurement of circulating GHRH levels by fluorescence immunoassay levels and immunohistochemical study of the primary lung tumor and metastatic tissue with anti-GHRH and anti-somatostatin receptor type 2 (sst2A) antibodies.
  • Pathological study of liver and bone biopsy material and lung tissue removed 19 years earlier was consistent with an atypical carcinoid producing GHRH and exhibiting sst2A receptor expression.
  • [MeSH-major] Antineoplastic Agents, Hormonal / therapeutic use. Bronchial Neoplasms / secondary. Bronchial Neoplasms / secretion. Carcinoid Tumor / secondary. Carcinoid Tumor / secretion. Growth Hormone-Releasing Hormone / secretion. Hormones, Ectopic / secretion. Human Growth Hormone / secretion. Octreotide / therapeutic use

  • Genetic Alliance. consumer health - Carcinoid Tumor.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Endocrinol Metab. 1988 Aug;67(2):395-9 [2899089.001]
  • [Cites] J Clin Endocrinol Metab. 1999 Sep;84(9):3162-9 [10487681.001]
  • [Cites] Endocr Rev. 1988 Aug;9(3):357-73 [3145190.001]
  • [Cites] J Clin Invest. 1986 Oct;78(4):906-13 [3093533.001]
  • [Cites] N Engl J Med. 1996 Jan 25;334(4):246-54 [8532003.001]
  • [Cites] Neurosurgery. 2002 Jun;50(6):1356-9; discussion 1360 [12015856.001]
  • [Cites] Endocr Rev. 1998 Dec;19(6):798-827 [9861546.001]
  • [Cites] Endokrynol Pol. 2006 Jan-Feb;57(1):32-6 [16575760.001]
  • [Cites] J Clin Endocrinol Metab. 2005 Apr;90(4):2104-9 [15671091.001]
  • [Cites] Clin Endocrinol (Oxf). 2002 Jul;57(1):131-4 [12100081.001]
  • [Cites] J Thorac Cardiovasc Surg. 1985 Jun;89(6):819-25 [2582209.001]
  • [Cites] Endocrinol Metab Clin North Am. 1991 Sep;20(3):507-18 [1935918.001]
  • [Cites] J Clin Endocrinol Metab. 2005 Nov;90(11):6156-61 [16091489.001]
  • [Cites] Clin Endocrinol (Oxf). 1991 Jun;34(6):463-7 [1653654.001]
  • [Cites] Science. 1998 Jan 23;279(5350):563-6 [9438850.001]
  • [Cites] Cancer. 1988 Jan 15;61(2):221-6 [2891432.001]
  • [Cites] Ann Oncol. 2001;12 Suppl 2:S89-94 [11762359.001]
  • [Cites] Am J Surg Pathol. 2005 Dec;29(12):1642-51 [16327437.001]
  • [Cites] Neurochirurgia (Stuttg). 1992 Sep;35(5):160-2 [1436366.001]
  • [Cites] J Clin Invest. 1980 Jan;65(1):43-54 [6243140.001]
  • [Cites] Endocrinology. 1989 Aug;125(2):801-9 [2502376.001]
  • [Cites] Cancer Res. 1998 Jun 1;58(11):2375-8 [9622077.001]
  • [Cites] Cancer. 2004 Dec 1;101(11):2605-13 [15495181.001]
  • [Cites] Eur J Nucl Med. 1998 Jul;25(7):675-86 [9662588.001]
  • [Cites] J Laryngol Otol. 2005 May;119(5):405-8 [15949110.001]
  • [Cites] J Clin Endocrinol Metab. 1998 Sep;83(9):3104-9 [9745411.001]
  • [Cites] J Physiol Paris. 2000 May-Aug;94(3-4):205-10 [11087998.001]
  • [Cites] Am J Clin Pathol. 1986 Jan;85(1):13-20 [3000164.001]
  • [Cites] Ann Thorac Surg. 1996 Sep;62(3):798-809; discussion 809-10 [8784011.001]
  • [Cites] Endocr Relat Cancer. 2006 Sep;13(3):955-62 [16954443.001]
  • [Cites] Front Neuroendocrinol. 1999 Jul;20(3):157-98 [10433861.001]
  • [Cites] Endocrinol Metab Clin North Am. 1992 Sep;21(3):575-95 [1521513.001]
  • [Cites] Clin Endocrinol (Oxf). 2004 Aug;61(2):224-31 [15272918.001]
  • [Cites] J Clin Endocrinol Metab. 1989 Feb;68(2):499-504 [2493033.001]
  • [Cites] Clin Endocrinol (Oxf). 2001 Jul;55(1):135-40 [11453963.001]
  • [Cites] Eur J Endocrinol. 1995 Sep;133(3):320-4 [7581949.001]
  • (PMID = 17373589.001).
  • [ISSN] 1386-341X
  • [Journal-full-title] Pituitary
  • [ISO-abbreviation] Pituitary
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 0 / Blood Glucose; 0 / Hormones, Ectopic; 0 / Radiopharmaceuticals; 0 / Receptors, Somatostatin; 12629-01-5 / Human Growth Hormone; 9034-39-3 / Growth Hormone-Releasing Hormone; RWM8CCW8GP / Octreotide
  •  go-up   go-down


59. Brosseuk D, Oosthuizen J, Pinchbeck M: Initial experience with a general population colorectal cancer screening clinic. Am J Surg; 2006 May;191(5):669-72
MedlinePlus Health Information. consumer health - Colorectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Colorectal cancer is, therefore, an ideal malignancy for preventative screening given the presence of a benign precursor.
  • Those patients found to have adenomas or carcinomas were analyzed further regarding location of neoplasm and pathologic findings.
  • A total of 152 patients had polyps removed, of which 63 patients had adenomas, 3 had adenocarcinomas, 1 had a carcinoid, and the remaining had an assortment of nonneoplastic polyps.
  • All 3 patients with carcinoma had early tumors resected with curative intent, with negative margins and negative nodes.
  • [MeSH-major] Cancer Care Facilities. Colonoscopy. Colorectal Neoplasms / diagnosis. Mass Screening / methods
  • [MeSH-minor] Aged. Aged, 80 and over. British Columbia / epidemiology. Diagnosis, Differential. Female. Humans. Male. Middle Aged. Retrospective Studies. Risk Factors. Video Recording

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colonoscopy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16647357.001).
  • [ISSN] 0002-9610
  • [Journal-full-title] American journal of surgery
  • [ISO-abbreviation] Am. J. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


60. Granberg D, Eriksson B, Janson ET, Oberg K, Skogseid B: [Lung carcinoids--not so benign as earlier believed]. Lakartidningen; 2006 Aug 23-29;103(34):2382-4
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Lung carcinoids--not so benign as earlier believed].
  • [MeSH-major] Carcinoid Tumor. Lung Neoplasms
  • [MeSH-minor] Follow-Up Studies. Humans. Neoplasm Recurrence, Local. Prognosis

  • MedlinePlus Health Information. consumer health - Carcinoid Tumors.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16972494.001).
  • [ISSN] 0023-7205
  • [Journal-full-title] Läkartidningen
  • [ISO-abbreviation] Lakartidningen
  • [Language] swe
  • [Publication-type] Journal Article; Review
  • [Publication-country] Sweden
  • [Number-of-references] 20
  •  go-up   go-down






Advertisement